[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 242
1. Kim KH, Sul HJ, Kang DY: Sclerosing hemangioma with lymph node metastasis. Yonsei Med J; 2003 Feb;44(1):150-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma with lymph node metastasis.
  • Sclerosing hemangioma (SH) of the lung is an uncommon type of tumor, which is composed of polygonal and cuboidal cells.
  • This disease is generally regarded as benign but extremely rare cases with lymph node metastasis have been reported.
  • We report a case of SH with a metastasis to the regional lymph nodes.
  • A 19-year-old girl presented with a 2-year history of coughing.
  • As a result, a left lower lobectomy with a dissection of the hilar and interlobar lymph nodes was performed.
  • Both types of tumor cells were uniformly immunoreactive to the epithelial membrane antigen (EMA) and the thyroid transcription factor-1 (TTF-1).
  • Postoperatively, the patient received chemotherapy and no recurrence or metastasis 2 years after surgery was noted.
  • Although a pulmonary SH is considered to be benign, this case highlights the need for the evaluation of lymph node metastasis.
  • [MeSH-major] Hemangioma / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619190.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • This review gives an outline of chemotherapy and the newer targeted therapies for the same.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • The available data from the literature is mainly composed of the most recent reviews, meta-analyses, phase II, and randomized phase III trials published in various peer reviewed journals and various international conferences.
  • The role of neoadjuvant and adjuvant chemotherapy has been found to be controversial.
  • The recent meta-analysis for adjuvant therapy in STSs has shown an increase in the overall survival with combination of ifosfamide and adriamycin.
  • In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication.
  • Newer combinations of docetaxel and gemcitabine appear promising in selected subgroups, especially in leiomyosarcoma and malignant fibrous histiocytoma.
  • Some recent developments include the European Union's approval of trabectedin for advanced STSs patients who had progressed on adriamycin and ifosfamide therapy.
  • The future of mTOR inhibitors, insulin like growth factor receptor inhibitors and anti-angiogenic drugs appear quite promising.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • At the end of each section we have also presented recommendations from FNx01European Society of Medical Oncology and FNx08National Comprehensive Cancer Network guidelines v.1.2009 for better correlation with the present literature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


3. Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB: Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res; 2008 Jun;466(6):1292-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.
  • The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [3, 5, 6, 20, 22, 35].
  • We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival.
  • We report the results of treating 53 adults (age 18-77 years) diagnosed with nonmetastatic extremity osteosarcoma or malignant fibrous histiocytoma.
  • Preoperative chemotherapy consisted of intravenous doxorubicin followed by intraarterial cisplatinum administered repetitively every 3 weeks for three to five cycles, depending on tumor response assessed by serial arteriography.
  • After resection, good responders (90% or greater necrosis) underwent treatment with the same agents and poor responders were treated with alternative agents for longer duration.
  • LEVEL OF EVIDENCE: Level III, therapeutic study.
  • See the Guidelines for Authors for a complete description of levels of evidence.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Neoplasms / drug therapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Histiocytoma, Malignant Fibrous / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arm Bones. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Leg Bones. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Ann Oncol. 1992 Apr;3 Suppl 2:S3-6 [1622860.001]
  • [Cites] Chir Organi Mov. 1996 Sep-Dec;81(4):369-82 [9147928.001]
  • [Cites] Clin Orthop Relat Res. 1997 Apr;(337):216-25 [9137193.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):765-71 [9332684.001]
  • [Cites] Acta Oncol. 1998;37(1):41-8 [9572653.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):423-31 [8113851.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):135-42 [7785572.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):631-7 [10203605.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:58-61 [10429624.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):949-56 [10491520.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10):1637-43 [10520703.001]
  • [Cites] Clin Orthop Relat Res. 2004 Dec;(429):286-91 [15577500.001]
  • [Cites] J Vasc Interv Radiol. 2005 Aug;16(8):1107-19 [16105923.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:128-36 [16131881.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8845-52 [16246977.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1154-61 [16421923.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):112-28 [17227995.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):118-23 [17577221.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):458-64 [10774566.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):874-81 [11079583.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] J Chemother. 2001 Feb;13(1):93-9 [11233808.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):498-507 [12794015.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] JAMA. 1972 Sep 4;221(10):1132-8 [4512088.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Med Pediatr Oncol. 1978;4(2):127-32 [275532.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):248-54 [6936069.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):1-4 [6263447.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):402-7 [6571796.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1101-4 [3874932.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):194-202 [3164231.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):63-7 [2910425.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):839-42 [2916040.001]
  • [Cites] Skeletal Radiol. 1990;19(3):165-72 [2185556.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1703-10 [2208024.001]
  • [Cites] Clin Orthop Relat Res. 1991 Mar;(264):156-68 [1997230.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):489-94 [1911456.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):269-73 [1793151.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):411-5 [9010116.001]
  • (PMID = 18437502.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2384032
  •  go-up   go-down


Advertisement
4. Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS: Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer; 2001 Jul 20;85(2):157-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
  • This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI).
  • 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues.
  • There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours.
  • The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space.
  • Tumour response in the whole group to treatment was partial response: 53.8% (n = 7); complete response: 33.3% (n = 5); no response: 6.7% (n = 1).
  • There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01).
  • It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI.
  • The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation.
  • The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Melphalan / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Merkel Cell / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Humans. Melanoma / drug therapy. Microdialysis. Middle Aged. Osteosarcoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):47-54 [10711640.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 [6891640.001]
  • [Cites] Am J Physiol. 1984 May;246(5 Pt 2):R665-77 [6720989.001]
  • [Cites] J Pharmacokinet Biopharm. 1988 Feb;16(1):41-83 [3373419.001]
  • [Cites] J Intern Med. 1991 Oct;230(4):365-73 [1919432.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1811-3 [1389515.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):151-3 [8018528.001]
  • [Cites] J Pathol. 1995 Jul;176(3):279-87 [7674090.001]
  • [Cites] Melanoma Res. 1995 Dec;5(6):425-31 [8589617.001]
  • [Cites] Cancer Lett. 1996 Feb 6;99(2):225-31 [8616828.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):920-4 [8611407.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 Nov 17;673(2):267-79 [8611961.001]
  • [Cites] Br J Surg. 1996 Oct;83(10):1319-28 [8944445.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):267-72 [8996531.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):19-26 [9067961.001]
  • [Cites] Melanoma Res. 1997 Jun;7(3):252-64 [9195565.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2598-601 [9205062.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):903-7 [9267277.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):238-47 [9548607.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2982-5 [9679959.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2906-12 [9738557.001]
  • [Cites] Electrophoresis. 1998 Nov;19(16-17):2981-5 [9870399.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):522-30 [10235581.001]
  • [Cites] Ann Pharmacother. 1999 Jun;33(6):730-8 [10410188.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1000-3 [10737379.001]
  • (PMID = 11461070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2364039
  •  go-up   go-down


5. Miyagawa-Hayashino A, Tazelaar HD, Langel DJ, Colby TV: Pulmonary sclerosing hemangioma with lymph node metastases: report of 4 cases. Arch Pathol Lab Med; 2003 Mar;127(3):321-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary sclerosing hemangioma with lymph node metastases: report of 4 cases.
  • CONTEXT: Sclerosing hemangioma is an unusual pulmonary tumor.
  • Previously, 4 patients with pulmonary sclerosing hemangioma and lymph node metastases have been described in the literature.
  • OBJECTIVE: To report 4 additional cases of metastatic sclerosing hemangioma.
  • RESULTS: Four cases of a morphologically benign pulmonary sclerosing hemangioma with regional lymph node metastases (including hilar, peribronchial, and interlobar metastases) were identified.
  • The pulmonary tumors were typical circumscribed sclerosing hemangiomas without mitotic activity, angiolymphatic invasion, or necrosis.
  • One patient received adjuvant chemotherapy for adenocarcinoma.
  • CONCLUSIONS: On the basis of case data from the 4 patients described here and the 4 patients described previously, metastases to regional lymph nodes from pulmonary sclerosing hemangioma may occur but are rare and do not appear to affect prognosis.
  • [MeSH-major] Hemangioma / diagnosis. Lung Neoplasms / diagnosis. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12653576.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D: Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One; 2010;5(4):e9747
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.
  • BACKGROUND: Diagnosis of soft tissue sarcomas (STS) is challenging.
  • Many remain unclassified (not-otherwise-specified, NOS) or grouped in controversial categories such as malignant fibrous histiocytoma (MFH), with unclear therapeutic value.
  • We analyzed several independent microarray datasets, to identify a predictor, use it to classify unclassifiable sarcomas, and assess oncogenic pathway activation and chemotherapy response.
  • We developed and validated a predictor, which was used to reclassify MFH and NOS sarcomas.
  • Bayesian models of oncogenic pathway activation and chemotherapy response were applied to individual STS samples.
  • A 170-gene predictor was developed and independently validated (80-85% accuracy in all datasets).
  • Most MFH and NOS tumors were reclassified as leiomyosarcomas, liposarcomas and fibrosarcomas.
  • This classification revealed previously unrecognized tissue differentiation lines (adipocyte, fibroblastic, smooth-muscle) and was reproduced in paraffin specimens.
  • CONCLUSIONS/SIGNIFICANCE: STS profiling can aid in diagnosis through a predictor tracking distinct tissue differentiation in unclassified tumors, and in therapeutic management via oncogenic pathway activation and chemotherapy response assessment.
  • [MeSH-major] Bayes Theorem. Neural Networks (Computer). Oligonucleotide Array Sequence Analysis. Sarcoma / classification. Sarcoma / genetics
  • [MeSH-minor] Cluster Analysis. Databases, Nucleic Acid. Drug Resistance, Neoplasm / genetics. Expert Systems. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Soft Tissue Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):77-80 [11250749.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Curr Oncol Rep. 2001 May;3(3):243-9 [11296135.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):330-9 [18286476.001]
  • [Cites] Methods Mol Biol. 2008;439:159-77 [18370102.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Expert Opin Ther Targets. 2008 May;12(5):589-603 [18410242.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):543-8 [14962721.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1799-807 [15509548.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:318-26 [9474886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5881-9 [15994966.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6280-90 [16144932.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7332-41 [16145063.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Biostatistics. 2007 Jan;8(1):118-27 [16632515.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):517-25 [17290060.001]
  • [Cites] Clin Transl Oncol. 2007 Mar;9(3):130-44 [17403624.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] PLoS One. 2007;2(10):e1002 [17912341.001]
  • [Cites] PLoS One. 2007;2(11):e1195 [18030330.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):346-51 [18199526.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):1-9 [18187804.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • (PMID = 20368975.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2848563
  •  go-up   go-down


7. Kocer B, Gulbahar G, Erdogan B, Budakoglu B, Erekul S, Dural K, Sakinci U: A case of radiation-induced sternal malignant fibrous histiocytoma treated with neoadjuvant chemotherapy and surgical resection. World J Surg Oncol; 2008;6:138
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of radiation-induced sternal malignant fibrous histiocytoma treated with neoadjuvant chemotherapy and surgical resection.
  • BACKGROUND: Primary sternal malignant fibrous histiyocytoma (MFH) is highly rare.
  • Effective treatment modality is surgical resection with wide margins.
  • However, to date, the effects of radiotherapy or chemotherapy has not been clearly defined.
  • CASE PRESENTATION: Herein, we aimed to present a 50-year old female patient with MFH occurred in the radiotherapy field who had had surgical procedure for breast cancer 19 years ago and had followed by radiotherapy.
  • Neoadjuvant chemotherapy was applied for MFH due to cardiac and mediastinal vascular invasion.
  • Wide resection was carried out for the mass after having been decreased in size following neoadjuvant chemotherapy.
  • CONCLUSION: Neoadjuvant chemotherapy was an effective method.
  • In planning the surgical resection, the size of the tumor before chemotherapy should be considered as the initial size and surgical margins should be determined accordingly.
  • [MeSH-major] Bone Neoplasms / therapy. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy / adverse effects. Sternum / radiation effects
  • [MeSH-minor] Breast Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jan 1;45(1):167-78 [6243239.001]
  • [Cites] Surg Clin North Am. 1980 Aug;60(4):779-91 [6999648.001]
  • [Cites] Diagn Interv Radiol. 2005 Mar;11(1):23-7 [15795839.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Sep;90(3):367-72 [4033174.001]
  • [Cites] Ann Thorac Surg. 1986 Jun;41(6):597-601 [3013106.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jan;111(1):96-105; discussion 105-6 [8551793.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):371-4 [11888478.001]
  • [Cites] J Thorac Cardiovasc Surg. 1986 Feb;91(2):234-7 [3003463.001]
  • (PMID = 19116008.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2628670
  •  go-up   go-down


8. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Goto T, Kosaku H, Kobayashi H, Hozumi T, Kondo T: [Soft tissue sarcoma: postoperative chemotherapy]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1324-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma: postoperative chemotherapy].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • The efficacy of chemotherapy varies according to the histological type of sarcoma.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy.
  • On the other hand, the efficacy of chemotherapy is not statistically demonstrated in non-round cell sarcomas, e. g., malignant fibrous histiocytoma.
  • Nowadays, several kinds of antitumor agents are usually used for adjuvant chemotherapy, and many authors have reported various kinds of regimens and their clinical results.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate, cyclophosphamide, dacarbazine, vincristine, and actinomycin-D.
  • Recently, high-dose chemotherapy combined with autologous peripheral blood or bone marrow stem cell transplantation has been begun in patients who do not respond to standard chemotherapy, and a better prognosis is expected.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Melphalan / administration & dosage. Mesna / administration & dosage. Methotrexate / administration & dosage. Osteosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446551.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; MAID protocol; VAIA protocol
  • [Number-of-references] 76
  •  go-up   go-down


10. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Yamamura R, Yamane T, Aoyama Y, Nakamae H, Makita K, Shima E, Ohta K, Inoue T, Sakamoto H, Hino M: Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma. Acta Haematol; 2003;109(3):141-4
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma.
  • At the age of 28, a 33-year-old male was diagnosed with malignant fibrous histiocytoma (MFH) with a primary lesion in the right maxillary sinus.
  • Although arterial infusion chemotherapy (pirarubicin hydrochloride and carboplatin) was given, no tumor shrinkage was observed, and surgery was therefore performed to remove the tumor.
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment.
  • The clinical course of this patient strongly suggests that this was a case of treatment-related CML that developed after chemotherapy for MFH.
  • Treatment-related malignant blood diseases are known to include acute myelocytic leukemia and myelodysplastic syndrome, but reports of treatment-related CML are rare, although there have been some cases of treatment-related CML occurring several years after pretreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Histiocytoma, Benign Fibrous / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Maxillary Sinus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12714824.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Hoshi M, Takami M, Ieguchi M: Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. Radiat Med; 2008 Oct;26(8):499-503
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
  • We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously.
  • Although these metastases responded well to systemic chemotherapy, brain metastases newly appeared and caused the death of the patient.
  • These findings demonstrate that individual sarcomatous metastatic organs exhibit different sensitivities to chemotherapy.
  • The mechanism of this phenomenon is discussed with a review of previous reports.
  • It is suggested that the blood-brain barrier may play an important role in sensitivity to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Histiocytoma, Malignant Fibrous / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Acetabulum. Bone and Bones / drug effects. Brain / drug effects. Doxorubicin / administration & dosage. Forearm. Humans. Ifosfamide / administration & dosage. Lung / drug effects. Male. Middle Aged


13. Machak GN, Polotskiĭ BE, Meluzova OM, Chernov IS, Aliev MD: [Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin]. Vopr Onkol; 2010;56(2):220-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
  • Our investigation involved 27 patients with osteosarcoma and 2--malignant fibrous histiocytoma of long tubular bones treated at the Center's Clinics (2001-2008).
  • Surgical treatment used atypical resection of the lung or precision excision of metastasis.
  • Metastases were removed after a course of chemotherapy in 16 cases.
  • Hence, timely combination therapy of relapsed high-grade osteosarcoma may secure relatively long remission in 35-40.3%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Histiocytoma, Malignant Fibrous / drug therapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552902.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Chugh R, Thomas D, Wathen K, Thall PF, Benjamin RS, Maki RS, Samuels BL, Keohan ML, Priebat DA, Baker LH: Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):9001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.
  • METHODS: Patients ≥10 years old with a sarcoma subtype not curable by multidisciplinary management were eligible.
  • Rules for early termination within each disease type were based on a hierarchical Bayesian probability model accounting for correlation of the responses of the 10 disease types.
  • Tissue specimens were analyzed by immunohistochemistry for c-kit, PDGFRα, PDGFR****223'3f NEEDS TO BE ADDED TO TIMES NEW ROMAN GREEK FONT****, AKT, PTEN, FKHR, and by allelic PCR analysis for PDGFRα exon 18.
  • Patients received prior chemotherapy and all had progressive disease.
  • Four month progression-free survival (PFS) rates follow: all sarcoma subtypes 18% (27/147), angiosarcoma 10% (1/10), Ewing sarcoma 0% (0/13), fibrosarcoma 29% (2/7), liposarcoma 32% (9/28), leiomyosarcoma (LMS) 20% (6/30), malignant fibrous histiocytoma 1/15 (7%), osteosarcoma 18% (3/17), peripheral nerve sheath tumor 20% (1/5), rhabdomyosarcoma 0% (0/2), synovial sarcoma 20% (4/20).
  • CONCLUSIONS: Further investigation of imatinib in the therapy of liposarcoma, LMS, and fibrosarcoma is warranted.
  • The hierarchical Bayesian probability model is an effective method for studying rare diseases and their subtypes, when it is reasonable to assume that their response rates are exchangeable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis and treatment is unclear.
  • We analysed diseases outcomes (disease free survival, DFS) by histology high risk factors (tumor size, histology, and proliferation index).
  • Heterogeneous chemotherapy/radiotherapy schedules was evaluated .
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Adjuvant therapy was radiation 57.14% pts; and chemotherapy (doxorubicin 4/liposomal doxorubicin 2 pts) in recurrence.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Deckert PM, Siehl JM, Thiel E, Schmittel A, Hütter G, Szelényi H, Keilholz U: Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma.
  • : 9011 Background: Anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma.
  • METHODS: In a single-arm phase II study 40 patients were enrolled with a median age of 57 years (19 to 78 years).
  • Treatment regimen was L-Dauno 100 mg/m2 and ifosfamide 5 g/m2 over 24 h every 4 weeks with G-CSF support.
  • Initially, 5 patients were included after failure of a doxorubicin/ifosfamide regimen, but none of these responded.
  • Treatment had to be terminated due to a pseudo-allergic reaction to L-Dauno in one patient.
  • One patient had ifosfamide related acute renal failure and was further treated with L-Dauno alone.
  • Eleven (31,4 %) out of 35 patients without pretreatment achieved a PR, all after 2 treatment cycles, 6 patients (17,1 %) had stable disease and 12 patients (34,3 %) progressed; 6 patient were not evaluable (2 treatment unrelated early deaths, 2 lost to follow up, 1 adjuvant treatment, 1 to early to evaluate).
  • Median time to progression was 10 months, median overall survival 16 months.
  • PR with respect to histology was: 4/7 PNET, 1/6 leiomyosarcoma, 2/4 liposarcoma, 1/2 synovial sarcoma, 1/3 pleomorphic sarcoma, 1/1 malignant histiocytoma and 1/2 carcinosarcoma.
  • Four of the responding patients received a consolidating high-dose-chemotherapy with subsequent stem cell support.
  • CONCLUSIONS: IDx is a well tolerated and highly active chemotherapy regimen for first line treatment of soft tissue sarcoma, even in elderly patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013680.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kasper B, Ouali M, Van Glabbeke M, Blay J, Bramwell VH, Woll PJ, Schöffski P: Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):10573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials.
  • METHODS: Patients selected for analysis were treated in two randomized trials of adjuvant chemotherapy in STS (EORTC 62771 and 62931).
  • A total of 793 patients were included with a median follow-up (FU) of 8.74 years (AYA population: n = 161, median FU 9.46 years; patients ≥ 30 years: n = 632, median FU 8.62 years).
  • The variables of the multivariate analysis were gender, subtype and grade, tumor size and localization (limb vs. other), absence or presence of local recurrence and treatment (control arm vs. adjuvant chemotherapy).
  • RESULTS: Patients' characteristics were globally similar with two exceptions, histological subtype (p = 0.0043) and tumor size (p < .0001).
  • The commonest sarcoma subtype in the AYA population was synovial sarcoma (29 %), whereas leiomyosarcoma (18 %), malignant fibrous histiocytoma (MFH, 16 %) and liposarcoma (15 %) were more frequent in patients ≥ 30 years.
  • For OS, independent favorable prognostic factors were low grade and small tumor size for both groups; radical resection and MFH or liposarcoma subtype were factors of favorable prognosis for patients ≥ 30 years only.
  • For RFS, favorable prognostic factors were small tumor size and low grade for both groups; tumor location in the extremities was a factor of favorable prognosis for the AYA population only, whereas radical resection and adjuvant chemotherapy treatment were favorable factors for patients ≥ 30 years only.
  • Interestingly, adjuvant chemotherapy was associated with improved RFS only in patients ≥ 30 years.
  • The results may have further implications on the treatment of STS patients in different age groups as well as the design of future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Maeura Y, Ueda N, Matsunaga S, Ohta H, Okamoto S: [A case of malignant fibrous histiocytoma of mesocolon successfully resected after combined chemotherapy with epirubicin, CDDP and vincristine]. Gan To Kagaku Ryoho; 2000 Feb;27(2):299-302
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant fibrous histiocytoma of mesocolon successfully resected after combined chemotherapy with epirubicin, CDDP and vincristine].
  • We experienced a case of MFH of the sigmoid mesocolon which was successfully resected after preoperative combined chemotherapy.
  • The tumor had extensively invaded the surrounding tissue and an incisional biopsy was done.
  • Ten cycles of post-operative chemotherapy with doxorubicin were effective for a complete remission.
  • Three cycles of combined chemotherapy with epirubicin, CDDP and vincristine led to a regression of the tumor and no distant metastasis was found.
  • The tumor was successfully resected with a negative surgical margin.
  • The patient has been in good health for 7 years and 2 months after the second operation without further therapy.
  • In cases of MFH such as the present in which the patient is sensitive to chemotherapy, neoadjuvant chemotherapy might be effective in allowing minimal surgery and offering a better quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / surgery. Mesocolon. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Epirubicin / administration & dosage. Humans. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700905.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Yamauchi T, Misaki H, Arai H, Iwasaki H, Naiki H, Ueda T: An autopsy case of disseminated mucormycosis in a neutropenic patient receiving chemotherapy for the underlying solid malignancy. J Infect Chemother; 2002 Mar;8(1):103-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An autopsy case of disseminated mucormycosis in a neutropenic patient receiving chemotherapy for the underlying solid malignancy.
  • Here, we describe an autopsy case of disseminated mucormycosis in a neutropenic patient who was receiving chemotherapy for an underlying solid malignancy.
  • A 31-year-old Japanese man received cytotoxic chemotherapy with etoposide for the pulmonary metastasis of a secondary malignant fibrous histiocytoma.
  • This patient had long been treated with chemotherapeutic agents for this solid cancer and for the preceding eosinophilic granuloma, both of which were highly resistant to the therapy.
  • During the treatment with etoposide, his neutrophil count declined to less than 100/microl.
  • The chemotherapy was discontinued, and granulocyte colony-stimulating factor was administered.
  • The therapy-related severe neutropenia, and the probable impairment of the immune system, because of the previous chemotherapies, would have been responsible for this fatal infection.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Mucormycosis / etiology. Neutropenia / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957129.001).
  • [ISSN] 1341-321X
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Kozuka T, Kiura K, Katayama H, Fujii N, Ishimaru F, Ikeda K, Ueoka H, Hamasaki S, Yoshino T, Kashihara Y, Date H, Tanimoto M, Harada M: Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. Anticancer Res; 2002 Sep-Oct;22(5):2939-44
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
  • BACKGROUND: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series.
  • The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established.
  • One patient with malignant fibrous histiocytoma recurred with multiple lung metastases.
  • This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin.
  • During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / therapy. Humans. Ifosfamide / administration & dosage. Male. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12530021.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


21. Kusuzaki K, Shinjo H, Murata H, Takeshita H, Hashiguchi S, Nozaki T, Emoto K, Ashihara T, Hirasawa Y: Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities. Anticancer Res; 2000 Sep-Oct;20(5C):3813-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities.
  • We performed the present study to clarify the relationship between the DOX binding ability (%DB) and the histologic response, rate of decrease in tumor volume of malignant soft tissue tumors after preoperative chemotherapy and prognosis.
  • Nine malignant soft tissue tumors (4 liposarcomas, 3 synovial sarcomas, one malignant fibrous histiocytoma (MFH) and one extraskeletal osteosarcoma (EOS)) which arose at the extremities of adult patients were analyzed by the DOX binding assay using freshly biopsied specimens.
  • After preoperative chemotherapy including DOX or pirarubicin (THP), the rate of decrease in tumor volume was measured using magnetic resonance imaging, and the histologic response expressed as tumor necrosis to chemotherapy was also investigated.
  • All the patients, apart for one, were continuously disease-free after treatment.
  • These results suggest that in malignant soft tissue tumors, the rate of decrease in tumor volume after chemotherapy might be a better indicator for chemosensitivity than the histologic response and also that the DOX binding ability might be a good predictor for chemosensitivity before chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / pharmacokinetics. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Arm. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / pathology. Thigh

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268459.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin
  •  go-up   go-down


22. Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, Pringle J, Uscinska BM, Weeden S, Kirkpatrick A, Glabbeke Mv, Craft AW, European Osteosarcoma Intergroup: Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer; 2005 Jan;41(2):225-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
  • There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B).
  • Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles.
  • Median time to progression was 30 months (95% Confidence Interval (CI), 8-51 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months).
  • Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Rare Diseases / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Infusions, Intravenous. Lymphatic Metastasis. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome


23. Tanaka F, Li M, Hanaoka N, Bando T, Fukuse T, Hasegawa S, Wada H: Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg; 2005 May;79(5):1711-4; discussion 1714-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The pathologic diagnoses of pulmonary nodules were pulmonary metastases of breast cancer in 39 patients, primary lung cancer in 6, and other diagnoses in 7 (tuberculosis and hamartoma in 2 each; sclerosing hemangioma, organizing pneumonia, and paragohimiasis in 1 each).
  • The 5-year survival rate after pulmonary metastectomy of metastatic breast cancer patients was 30.8%, which was not better than those documented in metastatic breast cancer patients treated with modern chemotherapy.
  • CONCLUSIONS: Pulmonary metastectomy may not be the primary therapeutic option in metastatic breast cancer patients, and patients should be treated principally with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854960.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Mandal S, Mandal AK: Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma. Int J Clin Oncol; 2007 Feb;12(1):52-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma.
  • Malignant fibrous histiocytoma (MFH) originates from primitive mesenchymal cells and has the capacity for dual differentiation into histiocytes and fibroblasts.
  • MFH occurring as a secondary malignancy following radio-chemotherapy is rare and its exact incidence is not yet known.
  • Here we report a case of a 42-year-old man who developed MFH in his right knee over a period of more than 10 years after radio (44 Gy)-chemotherapy to treat Hodgkin's lymphoma.
  • [MeSH-major] Bone Neoplasms / etiology. Histiocytoma, Malignant Fibrous / etiology. Hodgkin Disease / therapy. Muscle Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Dacarbazine / adverse effects. Doxorubicin / adverse effects. Humans. Male. Mechlorethamine / adverse effects. Neoplasms, Radiation-Induced / etiology. Prednisone / adverse effects. Procarbazine / adverse effects. Radiotherapy, Adjuvant. Vinblastine / adverse effects. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003187 [16235316.001]
  • [Cites] J Laryngol Otol. 2003 Mar;117(3):224-6 [12648384.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):859-63 [15581174.001]
  • [Cites] Clin Radiol. 2001 Jan;56(1):22-9 [11162693.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1630-47 [16356126.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):622-4 [15762368.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):371-4 [11888478.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2004;23(2):145-51 [15163293.001]
  • (PMID = 17380442.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


25. Padula GD, Schmitz M: Adult paratesticular malignant fibrous histiocytoma treated with surgery, systemic chemotherapy and postoperative adjuvant radiotherapy. J Cancer Res Ther; 2006 Oct-Dec;2(4):201-2
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult paratesticular malignant fibrous histiocytoma treated with surgery, systemic chemotherapy and postoperative adjuvant radiotherapy.
  • Paratesticular malignant fibrous histiocytoma is an extremely rare malignancy of the scrotum.
  • We present here a case of a 57-year-old man with a diagnosis of high-grade malignant fibrous histiocytoma of the left intrascrotal region who underwent radical orchiectomy, systemic chemotherapy and postoperative radiotherapy.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Histiocytoma, Malignant Fibrous / therapy. Scrotum / radiation effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryptorchidism / complications. Erythema / etiology. Humans. Lipomatosis / complications. Male. Middle Aged. Orchiectomy. Radiotherapy, Adjuvant / adverse effects. Tinea / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998705.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Bölke E, Ruf L, Budach W, Reinecke P, Röhrborn A, Pape H, Schwarz A, Schmitt G, Aul C: Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr; 2005 Dec;117(23-24):833-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma created from fibroblast cells and characterized by a high rate of metastasis or recurrence with poor prognosis.
  • There was a high local recurrence and metastasis rate, and the patient was treated with radiotherapy and conventional chemotherapy followed by tandem high-dose chemotherapy and peripheral blood stem-cell transplantation.
  • We review the clinical picture of the tumor in this patient and discuss its diagnosis, pathogenesis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Thoracic Surgery. Transplantation, Autologous. Treatment Outcome


27. Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW: Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer; 2001 Sep 15;92(6):1550-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
  • BACKGROUND: The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas.
  • METHODS: The medical records of 43 consecutive patients with soft tissue or bone sarcomas who were treated with concurrent IFX and EBRT were reviewed.
  • Histologies were rhabdomyosarcoma (n = 16 patients), Ewing sarcoma (n = 10 patients), malignant fibrous histiocytoma (n = 9 patients), and other soft tissue sarcomas (n = 8 patients).
  • Treatment consisted of EBRT (median dose, 50.4 gray [Gy]) with concomitant IFX (median dose per cycle, 10.2 g/m(2)).
  • All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy.
  • Confluent moist desquamation (Grade 3) occurred in nine patients in the treatment field; no patient experienced Grade 4 local toxicity.
  • CONCLUSIONS: Local and systemic toxicities after the administration of therapeutic doses of IFX with concomitant EBRT appear comparable to those observed with either treatment alone.
  • These results support the design of prospective studies evaluating concurrent ifosfamide and radiation therapy for patients with sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Bone Neoplasms / therapy. Ifosfamide / administration & dosage. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Histiocytoma, Benign Fibrous / therapy. Humans. Infant. Male. Middle Aged. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 27
  •  go-up   go-down


28. Quadros CA, Vasconcelos A, Andrade R, Ramos RS, Studart E, Nascimento G, Trajano A: Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol; 2006;3:18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma.
  • This article is a case report of a high grade, radio-induced, breast malignant fibrous histiocytoma (undifferentiated high grade pleomorphic sarcoma), which developed in a 44-year old female, seven years after breast conservative surgery and radiotherapy for a T1N0M0 invasive left breast ductal carcinoma.
  • The sarcoma presented as a fast growing tumour, 9.5 cm in the largest diameter, with skin, left breast, chest wall muscle and rib invasion.
  • Neoadjuvant chemotherapy was performed with epirubicin and ifosfamide.
  • Extended radical surgery according to oncological standards and soft tissue reconstruction were carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3378-83 [11013278.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):66-72 [7834431.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):356-8 [12383902.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1832-40 [12673708.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):856-63 [15981282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7 [1648044.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • (PMID = 16824232.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1538603
  •  go-up   go-down


29. Shioya T, Yuzuriha R, Maejima K, Mizutani S, Nambu K, Hoshino A, Shibuya T, Tokunaga A, Matsumoto K, Tajiri T: Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy. Clin J Gastroenterol; 2008 Oct;1(3):122-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy.
  • Malignant fibrous histiocytoma of the liver is an extremely rare tumor.
  • Histopathologically, the tumor was diagnosed as a primary storiform-pleomorphic-type malignant fibrous histiocytoma of the liver.
  • One year after the radical operation, the patient developed recurrences in other organs.
  • She received 17 cycles of chemotherapy with etoposide, ifosfamide, and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1992 Sep;21(3):290-2 [1328016.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):620-3 [17085355.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):386-91 [10390563.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W481-9 [17056878.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1331-9 [15446552.001]
  • (PMID = 26193650.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Liver / Malignant fibrous histiocytoma / Sarcoma / Surgery
  •  go-up   go-down


30. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative adjuvant therapy for primary malignant bone tumors].
  • In primary bone sarcomas, the efficacy of chemotherapy varies according to the histological types.
  • However, because these sarcomas are chemosensitive, their prognoses have been improved with adjuvant chemotherapy.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • In contrast, chondrosarcomas are chemoresistant, and chemotherapy is rarely performed.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • To enhance the efficacy of preoperative chemotherapy, various modalities have been used e. g., intraarterial infusion, caffeine-assisted chemotherapy, and local perfusion with hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down


31. Akai T, Yamamoto K, Iida T, Iizuka H, Nojima T: Malignant fibrous histiocytoma in the craniocervical junction presenting with severe occipitalgia. Brain Tumor Pathol; 2006 Oct;23(2):101-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma in the craniocervical junction presenting with severe occipitalgia.
  • The tumor demonstrated no definitive sarcoma differentiation and was identified as malignant fibrous histiocytoma.
  • After tumor resection, the patient received adjuvant radiation and chemotherapy.
  • Chemotherapy with ifosfamide, cisplatin, and etoposide caused remarkable tumor reduction, but suspension of chemotherapy resulted in tumor recurrence.
  • The results of our drug protocol suggest that this regimen is feasible as postoperative adjuvant chemotherapy for malignant fibrous histiocytoma.
  • The role of adjuvant chemotherapy and radiation therapy for this highly malignant rare tumor should be evaluated in a prospective study with precise histological diagnosis.
  • [MeSH-major] Atlanto-Occipital Joint / pathology. Head and Neck Neoplasms / pathology. Headache / etiology. Histiocytoma, Malignant Fibrous / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Fracture Fixation. Humans. Magnetic Resonance Imaging. Middle Aged. Neck Muscles / pathology. Neurosurgical Procedures. Occipital Lobe. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095127.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Neda H, Maeda M, Moriya H, Inohara T, Fujita T, Doi T, Nakajima T, Tanaka I, Ohhira N, Takeda M, Gotoh M: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to cisplatin, ifosfamide and doxorubicin]. Gan To Kagaku Ryoho; 2001 Jun;28(6):849-53
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to cisplatin, ifosfamide and doxorubicin].
  • A 61-year-old man was admitted to our hospital in December 1994 for a suspected retroperitoneal tumor.
  • Systemic imaging investigations demonstrated retroperitoneal solid tumor, which was diagnosed as malignant fibrous histiocytoma (MFH) by immunohistochemistry for alpha 1-antitrypsin.
  • In March 1995, he was treated with 3 courses of systemic chemotherapy with cisplatin, ifosfamide and doxorubicin followed by the same therapy in March 1996, without serious side effects.
  • MFH is known to be resistant to ordinary chemotherapy.
  • However, the CT showed a marked decrease in the size of the tumor, and the tumor disappeared within 2 months after the first treatment.
  • The present chemotherapy may be an effective treatment for retroperitoneal MFH.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432357.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


33. Saggia C, Forti G, Biaggi G, Lattuada S, Santagostino A, Angeli G, Pollo MC, Negru ME, Alabiso O: Two cases of secondary soft tissue sarcomas after radiotherapy and radiochemotherapy. Tumori; 2004 Nov-Dec;90(6):622-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of secondary soft tissue sarcomas after radiotherapy and radiochemotherapy.
  • BACKGROUND: The development of secondary soft tissue sarcomas after chemo-radiotherapy is a rare and little known event, but its frequency is increasing.
  • PATIENTS AND METHODS: We report two cases of secondary soft tissue sarcomas.
  • The first is the case of a 51-year-old woman treated for Hodgkin's disease with chemotherapy and radiotherapy 15 years before she developed a high-grade malignant pleural sarcoma.
  • The second is the case of a 64-year-old woman with a giant cell malignant histiocytoma secondary to colorectal cancer treated with surgery and radiotherapy nine years before.
  • Both were treated with chemotherapy (ifosfamide and epirubicin) without any relevant secondary effects; however, the response to therapy was poor.
  • CONCLUSIONS: The causes of secondary malignancies are multifactorial, but radiation therapy and chemotherapy are certainly implicated in the development of post-therapy neoplasms that are difficult to treat.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / adverse effects. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiotherapy. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Middle Aged. Radiotherapy, Adjuvant / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762368.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Saga K, Sato T, Abiko M, Takahashi N, Ikeda E: [A case of primary malignant fibrous histiocytoma of the lung]. Kyobu Geka; 2001 Mar;54(3):191-4
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant fibrous histiocytoma of the lung].
  • A 68-year-old woman presented with a complaint of coughing and chestroentgenography and computed tomography revealed a very large, irregular mass in the left inferior lobe of the lung.
  • The patient received preoperative chemotherapy including cisplatin with vindesine as employed for non-small cell lung cancer.
  • She demonstrated a clinical response after three cycles of the chemotherapy and underwent surgery successfully.
  • A postoperative diagnosis of MFH was made based on the histology of the tumor, which was pleomorphic with a storiform pattern.
  • The patient underwent a further three cycles of postoperative chemotherapy and has remained disease-free for 12 months after tumor resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244748.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


35. Minard-Colin V, Kalifa C, Guinebretiere JM, Brugieres L, Dubousset J, Habrand JL, Vassal G, Hartmann O: Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases. Br J Cancer; 2004 Feb 9;90(3):613-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analysed the clinical features and outcome of young patients with non-Ewing's flat bone sarcoma treated during the era of contemporary chemotherapy.
  • In all, 20 patients had osteosarcoma, four chondrosarcoma and one malignant fibrous histiocytoma.
  • The EFS rate of patients with second bone sarcoma was similar to that of patients with de novo flat bone sarcoma (P=0.1).
  • The aim of treatment was curative for 24 patients, 23 of whom were treated with intensive chemotherapy regimens and 19 with surgery.
  • Significant adverse prognostic factors on survival included incomplete surgical resection (P=0.001) and use of regimens without pre- and postoperative chemotherapy (P=0.007).
  • Nine of the 25 patients were treated with pre- and postoperative chemotherapy and complete surgical resection.
  • Nevertheless, our results suggest a more favourable outcome since the advent of intensive chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / pathology. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1993;29A(16):2284-91 [8110500.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1737-42 [1403056.001]
  • [Cites] Med Pediatr Oncol. 1996 Mar;26(3):180-5 [8544800.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:129-34 [9073059.001]
  • [Cites] Clin Orthop Relat Res. 1997 Apr;(337):226-39 [9137194.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1171-7 [9305720.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1611-8; discussion 1618-9 [9389923.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):170-4 [9434826.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):658-63 [9469355.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):851-9 [9486573.001]
  • [Cites] J Bone Joint Surg Am. 1999 Mar;81(3):326-38 [10199270.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):796-802 [10530839.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1164 [10561175.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2789-95 [10561354.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):324-32 [10640964.001]
  • [Cites] Cancer. 2000 May 1;88(9):2172-80 [10813731.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):171-82 [11134210.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):598-605 [11169944.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1201-12 [11283918.001]
  • [Cites] Clin Orthop Relat Res. 2001 May;(386):186-96 [11347833.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):340-8 [11563767.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1069-77 [11920477.001]
  • [Cites] J Pediatr. 1975 Feb;86(2):254-8 [1111694.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1221-30 [6174200.001]
  • [Cites] Clin Radiol. 1982 Mar;33(2):205-21 [6279350.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):130-4 [3006959.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):21-6 [3543236.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1178-84 [3476688.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1987;73(4):301-6 [3477842.001]
  • [Cites] Semin Diagn Pathol. 1987 Aug;4(3):212-36 [3313606.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Dec;13(12):1797-805 [3679916.001]
  • [Cites] Am J Surg Pathol. 1987 Dec;11(12):930-42 [3688300.001]
  • [Cites] Cancer. 1990 Feb 15;65(4):1011-6 [2297650.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1641-8 [2208016.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1766-75 [1717666.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] Ann Pathol. 1995;15(3):226-7 [7639864.001]
  • (PMID = 14760373.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409588
  •  go-up   go-down


36. Klopfenstein KJ, Scott S, Schuller DE, Ruymann FB: Prolonged survival with continuous infusion topotecan: a report of 2 cases. J Pediatr Hematol Oncol; 2008 Jun;30(6):468-70
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients with solid tumors were treated with 21-day continuous infusion topotecan as palliation therapy.
  • Case 2: A 17-year-old girl developed a malignant fibrous histiocytoma as a second malignant neoplasm.
  • After partial resection and failure of multiagent chemotherapy, she started continuous infusion topotecan and was disease-free for 58 months when she died of pneumonia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Head and Neck Neoplasms / drug therapy. Histiocytoma, Malignant Fibrous / drug therapy. Liver Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infusions, Intravenous. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / mortality. Palliative Care. Survival

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525467.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


37. Misaki H, Yamauchi T, Arai H, Yamamoto S, Sutoh H, Yoshida A, Tsutani H, Eguchi M, Nagoshi H, Naiki H, Baba H, Ueda T, Yamakawa M: Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis. J Clin Exp Hematop; 2009 May;49(1):33-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis.
  • We describe a rare case of secondary malignant fibrous histiocytoma (MFH) following Langerhans cell histiocytosis (LCH).
  • A biopsy specimen from the left iliac bone revealed an infiltration of S-100 protein-positive histiocyte-like cells intermingled with eosinophils, which confirmed the diagnosis of eosinophilic granuloma, a type of LCH.
  • Although the patient was treated with prednisolone initially, the disease did not respond well and progressed gradually over time.
  • The patient subsequently received multiple courses of chemotherapy and immunosuppressive therapy with many kinds of anticancer agents for 6 years.
  • He also received radiotherapy totaling 136.8 Gy for lung tumors and osteolytic lesions of the pelvis.
  • Although chemotherapy was continued, the patient died of pneumonia during the neutropenic period following chemotherapy.
  • LCH was not detected histologically in any tissues.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Histiocytosis, Langerhans-Cell / diagnosis
  • [MeSH-minor] Bone Diseases. Eosinophilic Granuloma / diagnosis. Eosinophilic Granuloma / drug therapy. Eosinophilic Granuloma / radiotherapy. Fatal Outcome. Humans. Lung Diseases. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / etiology. Pneumonia. Salvage Therapy / methods. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474515.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Abe T, Yamanaka K, Nakata W, Mori N, Sekii K, Yoshioka T, Itatani H: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report]. Hinyokika Kiyo; 2007 Apr;53(4):241-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report].
  • A 42-year-old male was referred to our hospital with a complaint of right lumbar pain in September 1999.
  • Abdominal computed tomography and magnetic resonance imaging revealed a large retroperitoneal tumor adjacent to the aorta and the renal vessels.
  • Histopathological examination showed a malignant fibrous histiocytoma (MFH).
  • Two cycles of systemic chemotherapy with pirarubicin, vincritine and cyclophosphamide were ineffective, then we tried concurrent cisplatin and radiation therapy.
  • Chemoradiation therapy showed a marked decrease in the size of the tumor, and the patient also recovered from right lumbar pain without serious side effects.
  • After chemoradiation therapy, we performed tumorectomy.
  • We performed repeatedly concurrent cisplatin and radiation therapy for the recurrent and metastatic tumor sites, and chemoradiation therapy led to regression of the tumors every time.
  • Concurrent cisplatin and radiation therapy might be an effective treatment for unresectable MFH.
  • [MeSH-major] Cisplatin / therapeutic use. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515074.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Staals EL, Bacchini P, Bertoni F: Dedifferentiated central chondrosarcoma. Cancer; 2006 Jun 15;106(12):2682-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma.
  • Radiographically, a soft tissue mass was present in 87% of patients, and a bimorphic pattern was appreciated in 53% of patients.
  • In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients).
  • For 101 patients, surgery was a component of their definitive management.
  • In 25 patients, surgery was combined with chemotherapy.
  • CONCLUSIONS: Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes.
  • There was no statistical evidence of any beneficial effect from adjuvant chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Combined Modality Therapy. Drug Therapy. Female. Femur / pathology. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / radiography. Histiocytoma, Malignant Fibrous / therapy. Humans. Humerus / pathology. Male. Middle Aged. Neoplasm Metastasis. Pelvis / pathology. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16691621.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ravi V, Benjamin RS: Systemic therapy for cardiac sarcomas. Methodist Debakey Cardiovasc J; 2010 Jul-Sep;6(3):57-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for cardiac sarcomas.
  • Most frequently, the histologies are angiosarcoma and high-grade pleomorphic unclassified sarcoma (formerly called MFH or malignant fibrous histiocytoma).
  • Conventional wisdom indicates that soft-tissue sarcomas are poorly responsive to chemotherapy.
  • Attempts to concentrate on the local problem only with therapies up to and including cardiac transplantation have been unsuccessful due to the high rate of fatal metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20834213.001).
  • [ISSN] 1947-6094
  • [Journal-full-title] Methodist DeBakey cardiovascular journal
  • [ISO-abbreviation] Methodist Debakey Cardiovasc J
  • [Language] eng
  • [Publication-type] Journal Article; Portraits
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Reinecke P, Steckstor M, Schmitz M, Gabbert HE, Gerharz CD: Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart. Oncol Rep; 2004 Mar;11(3):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart.
  • Primary malignant fibrous histiocytoma (MFH) of the heart is a rare and highly malignant soft tissue tumor, which is largely resistant to conventional chemotherapy and radiotherapy.
  • Therefore, we analyzed growth inhibitory effects of different chemotherapeutic agents and mechanisms of drug resistance in the recently established cell line MFH-H derived from a human primary cardiac MFH.
  • The expression and function of multidrug resistance-related proteins, i.e. the P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance-related protein (LRP) were determined by FACScan and functional assays of cellular drug efflux.
  • The concentration required for a 50% inhibition of growth (IC50) was 0.001 microM for etoposide and 0.035 microM for vincristine.
  • [MeSH-major] Alkaloids / therapeutic use. Drug Resistance, Multiple. Heart Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Plant Extracts / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Separation. Cell Survival. Cells, Cultured. Coloring Agents / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Etoposide / pharmacology. Flow Cytometry. Humans. Inhibitory Concentration 50. P-Glycoprotein / metabolism. Paclitaxel / pharmacology. Phenotype. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Vault Ribonucleoprotein Particles / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767515.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Coloring Agents; 0 / P-Glycoprotein; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 298-93-1 / thiazolyl blue; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


42. Luba MC, Bangs SA, Mohler AM, Stulberg DL: Common benign skin tumors. Am Fam Physician; 2003 Feb 15;67(4):729-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common benign skin tumors.
  • Benign skin tumors are commonly seen by family physicians.
  • The ability to properly diagnose and treat common benign tumors and to distinguish them from malignant lesions is a vital skill for all family physicians.
  • Lipomas are technically subcutaneous soft tissue tumors, not skin tumors, and controversy exists about whether keratoacanthomas have malignant potential; however, both are discussed in this article because they are common tumors evaluated by family physicians.
  • Treatment includes excision, cryotherapy, curettage with or without electrodesiccation, and pharmacotherapy, and is based on the type of tumor and its location.
  • Generally, excision is the treatment of choice for lipomas, dermatofibromas, keratoacanthomas, pyogenic granulomas, and epidermoid cysts.
  • Cherry angiomas and sebaceous hyperplasia are often treated with laser therapy and electrodesiccation.
  • Common treatments for acrochordons and seborrheic keratoses are cryotherapy and shave excision.
  • Referral is indicated if the family physician is not confident with the diagnostic evaluation or treatment of a lesion, or if a biopsy reveals melanoma.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613727.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


43. Sarma N: Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol; 2009;10(4):264-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme.
  • He also had a primary malignant fibrous histiocytoma of the thigh that was amputated 5 years earlier.
  • A rash developed after 7 days of radio- and chemotherapy.
  • It was an extensive maculopapular rash that started over the temporal area of the head and rapidly spread, sparing only the distal limbs.
  • The peculiarity of the presentation in this case was that the brunt of the disease with severe skin denudation was localized to the surrounding areas of cranial radiotherapy.
  • The patient was also receiving oral phenytoin, diclofenac, and parenteral dexamethasone before chemotherapy was started.
  • These medications were continued, even after development of the skin rash, until well after full recovery from the skin lesions.
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Combined Modality Therapy / adverse effects. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Neck / pathology. Scalp / pathology. Thorax / pathology

  • Genetic Alliance. consumer health - Stevens-Johnson syndrome.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489660.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


44. Thomas DM, O'Sullivan B, Gronchi A: Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther; 2009 Aug;9(8):1145-57
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.
  • Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care.
  • Usually large at presentation they present particular challenges for both local treatment and systemic control.
  • The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma).
  • Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease.
  • Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Combined Modality Therapy. Drug Delivery Systems. Humans. Palliative Care / methods. Radiotherapy, Adjuvant / methods

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671034.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


45. Kitazono I, Saigenji H: [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment]. Kyobu Geka; 2007 Mar;60(3):221-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment].
  • We report a case of malignant fibrous histiocytoma (MFH) of the chest wall.
  • Chest computed tomography (CT) revealed a tumor located at right posterior chest wall.
  • In May 1997, resection of the tumor was done (the 3rd operation), but metastasis to the ribs (the 4th operation), subcutaneous tissue (the 5th operation), and local recurrence (the 6th operation) was found within 4 years postoperatively.
  • Resection was done for each metastasis, and postoperative radiotherapy (66 Gy) and chemotherapy (CYVADIC) were done.
  • Multidisciplinary treatment may provide longer survival for patients with MFH of the chest wall.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Malignant Fibrous / therapy. Thoracic Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Radiotherapy Dosage. Surgical Mesh. Survivors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352141.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CYVADIC protocol
  •  go-up   go-down


46. Check JH, Dix E, Cohen R, Check D, Wilson C: Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res; 2010 Feb;30(2):623-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
  • The present study evaluated the palliative effect of mifepristone in a variety of different types of human cancer.
  • PATIENTS AND METHODS: Mifepristone was given at 200 mg daily orally with permission from the Food and Drug Administration to people with widely metastatic human cancer no longer responsive to other chemotherapy regimens.
  • RESULTS: Improvement in pain and energy and/or length of life was found in thymic epithelial cell carcinoma, transitional cell carcinoma of the renal pelvis, leiomyosarcoma, pancreatic carcinoma, malignant fibrous histiocytoma and another case of adenocarcinoma of the colon.
  • CONCLUSION: Our data demonstrate a palliative role for the use of mifepristone in cancer therapy.
  • Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.
  • [MeSH-major] Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Neoplasms / drug therapy. Palliative Care. Receptors, Progesterone / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Female. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / pathology. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Leiomyosarcoma / drug therapy. Leiomyosarcoma / secondary. Male. Middle Aged. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Survival Rate. Thymus Neoplasms / drug therapy. Thymus Neoplasms / pathology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332480.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


47. Wang BG, Liang H, Cui QH, Wang JC, Liu JZ: [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases]. Zhonghua Zhong Liu Za Zhi; 2004 Jun;26(6):373-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases].
  • OBJECTIVE: To investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).
  • METHODS: The clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.
  • The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases.
  • The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months.
  • Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051).
  • Postoperative CHOP chemotherapy was not shown to be beneficial.
  • CONCLUSION: Chemotherapy remains the important method of cure.
  • The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatectomy. Postoperative Period. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Splenectomy. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312351.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


48. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol; 2000 Jul;12(4):330-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments in animal models provide preliminary data on the feasibility of gene therapy in osteosarcoma and chondrosarcoma.
  • Prediction of response to chemotherapy remains a major focus of imaging research.
  • Several clinicopathologic studies have explored the mechanisms underlying multidrug resistance in osteosarcoma patients receiving neoadjuvant chemotherapy.
  • HER2/erbB2 expression, linked to poor prognosis, has been proposed as a therapeutic target in osteosarcoma.
  • A retrospective analysis showed no value for dose intensification of doxorubicin/cisplatin, but the results of a prospective trial should be more informative.
  • Recent evidence confirms that secondary osteosarcomas and malignant fibrous histiocytomas of bone should be treated with aggressive chemotherapy regimens, similar to those used for osteosarcomas.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10888418.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 50
  •  go-up   go-down


49. Jebson PJ, Sullivan L, Murray PM, Athanasian EA: Malignant fibrous histiocytoma of the distal radius: a case report. J Hand Surg Am; 2004 Mar;29(2):194-200
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the distal radius: a case report.
  • We report a case of a primary malignant fibrous histiocytoma of the distal radius in a 46-year-old man.
  • Treatment involved en bloc resection, reconstruction with a nonvascularized free fibular autograft, and wrist arthrodesis combined with adjuvant chemotherapy.
  • At the 2-year follow-up evaluation the patient had a satisfactory outcome with complete radiographic union and no evidence of a local recurrence or metastasis.
  • Resection combined with autogenous fibular grafting and adjuvant chemotherapy appears to be an acceptable method for treating malignant fibrous histiocytoma of the distal radius in this patient.
  • [MeSH-major] Bone Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Radius
  • [MeSH-minor] Chemotherapy, Adjuvant. Fibula / transplantation. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Reconstructive Surgical Procedures. Transplantation, Autologous

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043888.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Virgili G, Di Stasi SM, Storti L, Orlandi A, Vespasiani G: Successful management of retroperitoneal malignant fibrous histiocytoma involving both kidneys. Scand J Urol Nephrol; 2000 Jun;34(3):208-10
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of retroperitoneal malignant fibrous histiocytoma involving both kidneys.
  • We report a rare case of a retroperitoneal inflammatory variant of malignant fibrous histiocytoma (MFH) involving both kidneys.
  • The best treatment for MFHs is surgery with radical excision of the tumor.
  • The patient underwent adjuvant chemotherapy and 4 years later survives in a fairly good condition.
  • [MeSH-major] Histiocytoma, Benign Fibrous / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Kidney / pathology. Magnetic Resonance Imaging. Male. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10961478.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWEDEN
  •  go-up   go-down


51. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • There were six malignant fibrous histiocytomas, five liposarcomas, four malignant peripheral nerve sheath tumours, three rhabdomyosarcomas, two leiomyosarcomas, one recurrent extraskeletal osteosarcoma and one angiosarcoma.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Surgery included flaps or skin grafts in five patients, arterial replacement in two and knee arthrodesis in one.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


52. Flege S, Kuhlen M, Paulussen M, Bielack S, Jürgens H: [Surgery of primary malignant bone tumors]. Orthopade; 2003 Nov;32(11):940-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Operative Therapie primär maligner Knochentumoren.
  • In some, surgery alone is sufficient, in others therapy will be based on a combined modality concept.
  • The combined modality approach in osteosarcomas or Ewing's tumors provides for additional elements of local therapy (radiotherapy) or systemic treatment (chemotherapy).
  • In highly malignant osteosarcoma, where wide margin surgery is of utmost importance, only 10-20% of patients will survive longer than 5 years without aggressive systemic chemotherapy.
  • In disseminated osteosarcoma, a curative treatment approach will also provide for surgical removal of all metastases.
  • Treatment of primary malignant fibrous histiocytoma (MFH) of bone is identical to osteosarcoma therapy.
  • Since radiotherapy appears to be marginally more effective than in osteosarcoma, both modalities of local therapy are used.
  • Systemic chemotherapy adds an additional benefit for improved survival.
  • Therapy for Ewing's tumor also follows a combined modality approach.
  • The introduction of systemic chemotherapy has raised 5-year survival rates from less than 10% to above 60%.
  • [MeSH-minor] Amputation / mortality. Clinical Trials as Topic. Combined Modality Therapy / methods. Combined Modality Therapy / mortality. Fibrosarcoma / mortality. Fibrosarcoma / pathology. Fibrosarcoma / surgery. Humans. Limb Salvage / mortality. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / mortality. Sarcoma, Ewing / pathology. Sarcoma, Ewing / surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1001-6 [9869222.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):561-9 [11900241.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):120-7 [9973983.001]
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):444-9 [10531567.001]
  • [Cites] Tumori. 1989 Oct 31;75(5):456-62 [2603221.001]
  • [Cites] Strahlenther Onkol. 1996 May;172(5):244-8; discussion 249 [8633255.001]
  • [Cites] Acta Orthop Scand. 1999 Aug;70(4):353-60 [10569265.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):225-40 [8425351.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):698-708 [1730120.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):683-4 [8636791.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1698-704 [10674016.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):39-46 [11165128.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1763-9 [8355043.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(11):1338-44 [11435062.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):467-76 [7852108.001]
  • [Cites] J Bone Joint Surg Am. 1994 May;76(5):649-56 [8175811.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Clin Orthop Relat Res. 2001 Nov;(392):394-9 [11716413.001]
  • [Cites] Cancer. 2001 Mar 15;91(6):1170-6 [11267963.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1818-29 [11251014.001]
  • [Cites] Skeletal Radiol. 2001 Oct;30(10 ):600-3 [11685485.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):600-5 [2066757.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):449-53 [8445419.001]
  • [Cites] Nuklearmedizin. 2001 Dec;40(6):215-20 [11797510.001]
  • [Cites] Paediatr Drugs. 2001;3(12):899-913 [11772151.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1069-77 [11920477.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1357-62 [2072139.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] J Pediatr Surg. 1988 Feb;23(2):146-51 [3422682.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2699-705 [7989947.001]
  • (PMID = 14615843.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Komdeur R, Plaat BE, van der Graaf WT, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ, Molenaar WM: Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer; 2003 May;39(7):909-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade.
  • The biological behaviour of different histological types and grades of soft tissue sarcomas (STS) varies.
  • This might result in a differing sensitivity to cytotoxic drugs.
  • Cross-resistance to functionally and structurally distinct natural-product drugs, known as multidrug resistance (MDR), is associated with the overexpression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and lung resistance-related protein (LRP).
  • The purpose of this study was to evaluate the expression of P-gp, MRP1 and LRP in STS according to their histological type and grade.
  • In 141 chemotherapy-naive STS patients, the expression of the three MDR proteins was detected by immunohistochemistry.
  • Nine histological types were documented.
  • P-gp expression was most pronounced in malignant fibrous histiocytoma (MFH), but was low in leiomyosarcomas.
  • In conclusion, P-gp, MRP1 and LRP are expressed in the majority of STS, but this expression varies according to the histological type.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. P-Glycoproteins / metabolism. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry / methods. Infant. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12706359.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCC4 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoproteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


54. Milicic D, Juretic A, Bulum J, Saric N, Bisof V, Jelic I, Jelasic D: Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases. J Card Surg; 2007 Nov-Dec;22(6):513-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases.
  • Malignant fibrous histiocytoma is an extremely rare primary malignant tumor of the heart.
  • The prognosis is poor with an average survival time of one year.
  • We report a case of recurrent left atrial malignant fibrous histiocytoma initially misdiagnosed as myxoma.
  • The patient underwent repeated surgical resections followed by chemotherapy.
  • Despite adjuvant chemotherapy, 18 months after initial diagnosis, definitive tumor relapse in left atrium was diagnosed.
  • This is the 48th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Muscle Neoplasms / diagnosis. Muscle, Skeletal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039217.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Topleninova DIu, Chergeshtov IuI, Boĭkova SP, Chumakov AA: [Morphological study of histiocytosis from Langerhans cells in jaw bones]. Arkh Patol; 2003 Jul-Aug;65(4):32-6
Genetic Alliance. consumer health - Histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birbek's bodies were found in Langerhans cells in all the biopsies confirming the diagnosis of Langerhans cell histiocytoma.
  • The structure of Birbek's bodies changed depending on the treatment--radiation or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518191.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


56. Maki RG: Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist; 2007 Aug;12(8):999-1006
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective. In the era of oral molecular kinase inhibitors, cytotoxic chemotherapy agents are somewhat overlooked, but remain the backbone of treatment for most cancers.
  • Patients with non-gastrointestinal stromal tumor sarcomas, such as leiomyosarcoma, liposarcoma, and undifferentiated high-grade pleomorphic sarcoma (formerly called malignant fibrous histiocytoma), have received doxorubicin and ifosfamide as the backbone of their treatment for over 15 years or more.
  • Results. Activity of gemcitabine and docetaxel is observed in leiomyosarcoma and undifferentiated high-grade pleomorphic sarcoma.
  • Conclusions. The combination of gemcitabine and docetaxel is an effective option for patients with metastatic sarcoma, increasing the armamentarium for the practicing oncologist in treating this heterogeneous group of diseases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Sarcoma / pathology. Taxoids / therapeutic use
  • [MeSH-minor] Drug Synergism. Humans


57. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF: Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol; 2008 Oct;15(10):2749-56
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
  • BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique for delivering high-dose regional chemotherapy.
  • We report our experience with ILI for the treatment of soft tissue sarcoma (STS).
  • In all patients, a high-dose cytotoxic drug combination was used.
  • The procedure was well tolerated.
  • Fourteen patients (67%) received ILI before definitive surgery.
  • CR and malignant fibrous histiocytoma tumor subtype were associated with a lower local recurrence rate.
  • A lower initial skin temperature (median 35.8 degrees C) was associated with a CR (P = .033).
  • Patients who had a steep increase in intramuscular temperature during the procedure were more likely to have a CR (P = .055).
  • Classification tree analysis identified patients with an initial PaO(2) of >/=194 mmHg as being more likely to have a CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Dactinomycin / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648882.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; Q41OR9510P / Melphalan
  •  go-up   go-down


58. Natarajan MV, Mohanlal P, Bose JC: Limb salvage surgery complimented by customised mega prostheses for malignant fibrous histiocytomas of bone. J Orthop Surg (Hong Kong); 2007 Dec;15(3):352-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage surgery complimented by customised mega prostheses for malignant fibrous histiocytomas of bone.
  • PURPOSE: To assess functional and oncological outcomes of patients with malignant fibrous histiocytomas of bone, after limb salvage surgery complimented by a customised prosthesis.
  • METHODS: Between May 1991 and December 2002, 15 men and 5 women (mean age, 42 years) with histologically proven malignant fibrous histiocytoma of bone underwent treatment involving limb salvage surgery complimented by a customised mega prosthesis.
  • The Kaplan-Meier 5-year survival rates of the patients treated without chemotherapy and with chemotherapy were 50% and 76%, respectively.
  • CONCLUSION: Limb salvage surgery with chemotherapy is a viable treatment option for patients with malignant fibrous histiocytoma of bone.
  • Such therapy improves quality of life and provides a useful and functional limb.
  • [MeSH-major] Bone Neoplasms / surgery. Histiocytoma, Malignant Fibrous / surgery. Limb Salvage. Prostheses and Implants
  • [MeSH-minor] Adolescent. Adult. Amputation. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162685.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Okamoto K, Kato S, Katsuki S, Wada Y, Toyozumi Y, Morimatsu M, Aoyagi S, Imaizumi T: Malignant fibrous histiocytoma of the heart: case report and review of 46 cases in the literature. Intern Med; 2001 Dec;40(12):1222-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the heart: case report and review of 46 cases in the literature.
  • A rare case of cardiac malignant fibrous histiocytoma (MFH) is reported.
  • Neither chemotherapy nor irradiation was administered.
  • The details of this case are presented with a review of the literature.
  • [MeSH-major] Heart Neoplasms / diagnosis. Histiocytoma, Benign Fibrous / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11813848.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 57
  •  go-up   go-down


60. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the ovary: a case report.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • Primary malignant fibrous histiocytoma of the ovary is extremely rare, with only three previously reported cases.
  • We reported a rare and uncommon localization of malignant fibrous histiocytoma in a 22-year-old woman.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Histopathologic examination revealed inflammatory, malignant fibrous histiocytoma.
  • The management of malignant fibrous histiocytoma is controversial because of the heterogenous nature of the disease.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer; 2008 Jul 15;113(2):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
  • METHODS: A retrospective case review of 22 patients with recurrent or refractory bone or soft-tissue sarcomas who received gemcitabine (at a dose of 675 mg/m(2) intravenously on Days 1 and 8) and docetaxel (at a dose of 75-100 mg/m(2) intravenously on Day 8) was undertaken.
  • RESULTS: The patients (ages 8-23 years) received a total of 109 courses of chemotherapy (median, 4 courses; range, 1-13 courses).
  • Seventeen patients had osteosarcoma, 2 patients had Ewing sarcoma family of tumors (ESFT), 1 patient had a malignant fibrous histiocytoma (MFH), 1 patient had a chondrosarcoma, and 1 patient had an undifferentiated sarcoma.
  • Further evaluation of this drug combination is warranted in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Osteosarcoma / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Dose-Response Relationship, Drug. Female. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484657.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


63. Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, Del Muro JG, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM: Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol; 2007 Feb;59(2):251-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
  • PURPOSE: Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen.
  • METHODS: Patients with ASTS, measurable disease, pretreated with chemotherapy, received gemcitabine 1,800 mg/m2 infused over 180 min followed by DTIC 500 mg/m2 (one cycle), every 2 weeks.
  • The influence of the sequence of administration on those parameters was examined to exclude potential drug interactions.
  • Pooled data from the Phase I and Phase II studies showed clinical benefit in patients with leiomyosarcomas (LMS) (57%) and malignant fibrous histiocytomas (MFH) (33%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Area Under Curve. Aspartate Aminotransferases / blood. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacokinetics. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / pharmacokinetics. Female. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Ifosfamide / pharmacokinetics. Infusions, Intravenous. Liver / drug effects. Liver / enzymology. Lung / drug effects. Lung / pathology. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736150.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 85622-93-1 / temozolomide; B76N6SBZ8R / gemcitabine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


64. Dorobantu M, Fruntelata A, Constantinescu D, Racoveanu I, Ardeleanu C, Tatu-Chitoiu G, Lazar IC: Primary left heart malignant fibrous histiocytoma. Eur J Echocardiogr; 2005 Jun;6(3):225-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary left heart malignant fibrous histiocytoma.
  • We present the case of a 53 years-old woman presenting with congestive heart failure and pleural and pericardial effusions, in whom transthoracic and transesophageal echocardiography revealed multilocular cardiac tumor involving the left atrium wall, extending into the pericardium.
  • Tumor was excised surgically and proved to be a malignant fibrous histiocytoma, primarily confined to the heart.
  • Despite surgery followed by chemotherapy, the patient died a few months later.
  • This is the 47th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Echocardiography. Heart Neoplasms / ultrasonography. Histiocytoma, Benign Fibrous / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894243.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Coleman J, Brennan MF, Alektiar K, Russo P: Adult spermatic cord sarcomas: management and results. Ann Surg Oncol; 2003 Jul;10(6):669-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We present a 20-year surgical experience with spermatic cord sarcoma, describe prognostic features, and evaluate the results of surgical and adjunctive treatments.
  • Disease-free survival was calculated, and prognostic factors such as tumor grade, size, extent of operation, and adjuvant therapy were analyzed.
  • The most common tumor types included liposarcoma (51%), leiomyosarcoma (19%), embryonal rhabdomyosarcoma (13%), and malignant fibrous histiocytoma (11%).
  • Twenty-nine (62%) patients had high-grade tumors, 21 (45%) were treated with adjuvant radiation, and 9 (19%) received chemotherapy.
  • We could not demonstrate a therapeutic effect of adjuvant radiation or chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Databases, Factual. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839852.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Wang J, Chen A, Luo Y: [Surgical management of limb salvage for osteogenic malignant tumors around knees]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):975-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the pathological examination, osteosarcoma was found in 11 patients, synoviosarcoma in 4 patients, malignant fibrous histiocytoma in 3 patients, and giant cell tumor of the bone in 19 patients.
  • All the patients underwent neoadjuvant chemotherapy for 1-2 courses before operation except the patients with giant cell tumor of the bone.
  • The patients underwent prosthesis replacement, allogenous bone grafting, bone cement with adriamycin filled, and postoperative chemotherapy.
  • CONCLUSION: Making an early diagnosis, recognizing the operative indication, choosing the operative method, and performing the preoperative and postoperative chemotherapy and/or radiotherapy are the keys to achieving an ideal limb-salvage surgery for osteogenic malignant tumors around the knees.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Male. Middle Aged. Prosthesis Implantation. Reconstructive Surgical Procedures. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140066.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The approach to the management of retroperitoneal tumors begins with a complete history and physical examination.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


68. Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T, Tomita K: Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res; 2000 Dec;(381):185-91
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a giant cell tumor 25 years after initial treatment.
  • The current authors report a patient in whom a malignant fibrous histiocytoma developed long after a benign giant cell tumor of bone was removed from the same site.
  • Twenty-five years after a benign giant cell tumor of the lateral condyle of the proximal tibia had been treated by curettage and iliac bone grafting without radiotherapy, a 53-year-old woman noted progressive pain and an enlarging mass in the same area.
  • Examination of an open biopsy specimen showed a high-grade malignant fibrous histiocytoma with some areas rich in giant cells.
  • After five courses of caffeine assisted intraarterial chemotherapy, the tumor was resected with an adequate margin, and the defect was reconstructed with an implanted prosthesis of corresponding shape.
  • The resected specimen showed a good histologic response (95% tumor necrosis) to preoperative chemotherapy.
  • Caffeine potentiated chemotherapy was effective in minimizing the extent of tumor excision, in this case of high-grade malignant fibrous histiocytoma representing transformation from a benign giant cell tumor.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Transformation, Neoplastic. Giant Cell Tumor of Bone / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasms, Second Primary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127655.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


69. Sharma H, MacDuff E, Jane MJ, Reid R: Sarcomatous change in the Pagetoid tibiae. Int Orthop; 2005 Oct;29(5):319-25
MedlinePlus Health Information. consumer health - Paget's Disease of Bone.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, there were three osteosarcomas and ten malignant fibrous histiocytomas.
  • Six patients received adjuvant radiotherapy and/or chemotherapy.
  • Post-operative complications included stump revision in two cases, non-union of a pathological fracture of the tibial tuberosity and a stress fracture.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1999 Oct;28(10):599-603 [10550540.001]
  • [Cites] Skeletal Radiol. 2001 Jul;30(7):378-83 [11499777.001]
  • [Cites] J Bone Joint Surg Br. 1969 May;51(2):205-24 [5253684.001]
  • [Cites] Am J Surg Pathol. 1981 Jan;5(1):47-59 [6941703.001]
  • [Cites] Skeletal Radiol. 1982;9(2):145-7 [6962546.001]
  • [Cites] J Rheumatol. 1999 Jan;26(1):150-5 [9918257.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1489-95 [6577936.001]
  • [Cites] Radiology. 1984 Sep;152(3):583-90 [6235535.001]
  • [Cites] Am J Clin Pathol. 1985 May;83(5):594-600 [3857854.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1442-9 [2418941.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jun;156(6):1199-203 [2028867.001]
  • [Cites] J Bone Joint Surg Br. 1983 May;65(3):299-307 [6573330.001]
  • (PMID = 16094541.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3456639
  •  go-up   go-down


70. Shioiri M, Seike K, Kametaka H, Makino H, Miura S, Okubo Y, Fujisaki K, Koyama T: [A case of primary retroperitoneal malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2357-8
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary retroperitoneal malignant fibrous histiocytoma].
  • Based on histological and immunohistochemical inspection, the tumor was diagnosed as malignant fibrous histocytoma (MFH) on retroperitoneum.
  • No treatment was undergone as the postoperative course was good, however, computed tomography (CT) for 8 months after the surgery showed the sign of local recurrence.
  • It has been reported that the prognosis of MFH was very poor and a surgical resection was the only treatment for MFH, or we are expecting to find an effective treatment quickly such as a new combined chemotherapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037421.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


72. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer; 2002 Jun 15;94(12):3225-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The authors evaluated gemcitabine in patients with histologically confirmed sarcomas; one prior exposure to chemotherapy treatment was allowed.
  • Treatment consisted of gemcitabine 1250 mg/m(2) intravenously over 30 minutes, every week x three, cycles repeated q28 days.
  • RESULTS: Twenty nine of 30 patients were evaluable; one patient refused to initiate study treatment.
  • The mean age was 50 years (range, 22-81 years); 59% were male, and 35% had an Eastern Cooperative Oncology Group performance status of 0 (vs. 1 or 2).
  • Patients were histologically classified as leiomyosarcoma (seven gastrointestinal, four retroperitoneal, two inferior vena caval, three of the extremity, and two uterine), synovial (two patients), malignant fibrous histiocytoma (two patients), fibrosarcoma (one patient), osteosarcoma (two patients), liposarcoma (one patient), hemangiosarcoma (one patient), or giant cell (one patient).
  • Eighty three percent of patients discontinued treatment due to progression and 14% due to toxicity/refusal.
  • Median time -to progression was 2.1 months (95% CI: 1.8-3.0).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115355.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


73. Shinozaki T, Kato K, Watanabe H, Yanagawa T, Ahmed AR, Takagishi K: Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue. J Orthop Sci; 2001;6(4):339-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue.
  • We prospectively followed 32 patients with soft-tissue malignant fibrous histiocytoma (MFH).
  • Parameters were age; sex; tumor size, location, and depth; operative method; chemotherapy; radiotherapy; and histology.
  • Male patients with deep-seated storiform-pleomorphic type MFH, receiving less comprehensive surgery, had the greatest risk of local recurrence or early metastases.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11479763.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


74. Franco Gutiérrez V, Llorente Pendás JL, Coca Pelaz A, Cabanillas Farpón R, Suárez Nieto C: Radiation-induced sarcomas of the head and neck. J Craniofac Surg; 2008 Sep;19(5):1287-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five patients diagnosed of head and neck cancer received irradiation to treat their diseases.
  • Later on, these patients developed new neoplasms in the irradiation fields (3 malignant fibrous histiocytoma, 1 osteosarcoma, and 1 angiosarcoma).
  • All of the patients underwent surgical treatment.
  • Three patients also needed neoadjuvant chemotherapy.
  • Wide excision is the treatment of choice for RISs.
  • Previous radiation therapy limits the dose that can be administered to the involved area, and the response rate to the chemotherapy is always poor.
  • [MeSH-minor] Adult. Aged. Female. Hemangiosarcoma / etiology. Hemangiosarcoma / surgery. Histiocytoma, Malignant Fibrous / etiology. Histiocytoma, Malignant Fibrous / surgery. Humans. Male. Middle Aged. Neoadjuvant Therapy. Osteosarcoma / etiology. Osteosarcoma / surgery. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812853.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Demiralp B, Erler K, Ozturan EK, Bek D, Ozdemir T, Kurt B: An uncommon presentation of malignant fibrous histiocytoma of the calcaneus. J Am Podiatr Med Assoc; 2007 May-Jun;97(3):218-22
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of malignant fibrous histiocytoma of the calcaneus.
  • Malignant fibrous histiocytoma of bone is the osseous counterpart of the tumor in soft tissue.
  • We describe a primary malignant fibrous histiocytoma of the calcaneal bone in a 21-year-old man.
  • The patient underwent neoadjuvant and adjuvant chemotherapy and below-the-knee amputation, and no local recurrence or metastasis was noted after 2 years of follow-up.
  • [MeSH-major] Bone Neoplasms / pathology. Calcaneus. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507531.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Marchese R, Bufo P, Carrieri G, Bove G: Malignant fibrous histiocytoma of the kidney treated with nephrectomy and adjuvant radiotherapy: a case report. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the kidney treated with nephrectomy and adjuvant radiotherapy: a case report.
  • Malignant fibrous histiocytoma (MFH) usually presents in the extremities or retroperitoneum.
  • Although radical nephrectomy is the most beneficial curative choice for this neoplasm, patients are often treated with adjuvant chemotherapy due to high risk of local recurrence and distant metastases.
  • We describe a case of a 68-year-old woman affected by MFH, treated with both nephrectomy and radiotherapy without systemic therapy showing an unexpected twenty-four-month postsurgery survival outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936124.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948928
  •  go-up   go-down


77. Sugihara T, Fujimura T, Kume H, Homma Y: Successful treatment of metastatic malignant fibrous histiocytoma of the kidney. Urol Int; 2010;85(1):118-20
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.
  • Malignant fibrous histiocytoma (MFH) of the kidney is a rare sarcoma that often undergoes local recurrence and/or distant metastasis.
  • However, little is known about the outcome of metastatic diseases.
  • We present the case of a 46-year-old male suffering from renal MFH with pulmonary metastasis, who has undergone complete response for 3 years after surgical resection and MAID chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytoma, Malignant Fibrous / therapy. Kidney Neoplasms / therapy. Lung Neoplasms / therapy. Nephrectomy. Thoracoscopy
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20516674.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


78. Carnero S, Terán P, Trillo E: Malignant fibrous histiocytoma arising in a gouty tophus at the second metacarpophalangeal joint. J Plast Reconstr Aesthet Surg; 2006;59(7):775-8
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma arising in a gouty tophus at the second metacarpophalangeal joint.
  • We report a case of concomitant malignant fibrous histiocytoma (MFH) and tophaceous deposit at the second metacarpophalangeal joint in a 76-year-old man.
  • The patient underwent surgical treatment, local radiotherapy and adjuvant chemotherapy and was disease free at the time of his last examination.
  • [MeSH-major] Arthritis, Gouty / complications. Histiocytoma, Malignant Fibrous / complications. Metacarpophalangeal Joint
  • [MeSH-minor] Aged. Combined Modality Therapy. Gout / complications. Humans. Immunohistochemistry / methods. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782578.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Akhter SA, McGinty J, Konys JJ, Giesting RM, Merrill WH, Wagoner LE: Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation. J Heart Lung Transplant; 2004 Dec;23(12):1447-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation.
  • Malignant fibrous histiocytoma (MFH) is an extremely rare primary cardiac tumor.
  • We describe a young patient who underwent orthotopic heart transplantation for an unresectable right ventricular MFH and presented 7 years later with a local recurrence in the native right atrium.
  • This was treated by complete resection of the right atrial tumor and adjuvant chemotherapy.
  • [MeSH-major] Heart Neoplasms / surgery. Heart Transplantation. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607678.001).
  • [ISSN] 1053-2498
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Carrión López P, Pastor Navarro H, Martínez Ruiz J, Giménez Bachs JM, Donate Moreno MJ, Polo Ruiz L, Pastor Guzmán JM, Martínez Sanchiz C, Ruiz Mondéjar R, Virseda Rodríguez JA: [Spermatic cord sarcomas: current status and report of four cases]. Arch Esp Urol; 2009 Apr;62(3):242-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sarcomas de cordón espermático: estado actual y presentación de cuatro casos clínicos.
  • OBJECTIVE: To study and review spermatic cord sarcomas, including symptoms, diagnosis, and treatment.
  • METHODS/RESULTS: We review the Spanish and international literature and report 4 new cases: 2 patients with well-differentiated spermatic cord liposarcomas (1 treated by simple tumorectomy), 1 patient with liposarcomatous degeneration of a previously excised atypical lipoma, and 1 patient operated for a malignant retroperitoneal fibrous histiocytoma with subsequent local recurrence in the paratesticular region.
  • They are diagnosed by imaging studies (ultrasound, computed tomography, magnetic resonance) and confirmed by histological examination.
  • Spermatic cord sarcomas are treated surgically; the efficacy of adjuvant treatments such as chemotherapy or radiation therapy is still under debate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554782.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


81. Shi X, Wu S, Zhao J: [Limb salvage with osteoarticular allografts after resection of proximal tibia bone]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):966-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1998 to 2003, 15 patients (7 males, 8 females; aged 14-56 yr. average 33) with bone tumor of the proximal tibia underwent osteoarticular allografts. among whom 7 had progressive giant cell tumor without any previous chemotherapy; 8 had malignant tumor with previous chemotherapy, including 6 patients with osteosarcoma, 1 with spindle cell sarcoma, and 1 with malignant fibrous histiocytoma.
  • RESULTS: The follow-up for an average of 21 months (range, 3-58 months) revealed that among the 8 patients with malignant tumor of the proximal tibia undergoing chemotherapy, 5 had union of the bone, 3 had no union of the bone; among the 3 patients, 2 had a complication of infection and 1 had a local recurrence.
  • According to the Mankin score, 2 patients had a perfect result, 2 good, 1 fair, and 3 poor, with a 50% effectiveness rate.
  • According to the Mankin score, 3 patients had a perfect result, 2 good, and 2 fair, with a 71% effectiveness rate.
  • CONCLUSION: The osteoarticular allograft of the proximal tibia has many advantages in spite of a relatively high rate of complications, and it is the limb salvage of choice for the progressive benign or malignant bone tumors of the proximal tibia.
  • [MeSH-minor] Adolescent. Adult. Bone Transplantation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140064.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


82. Chow E, Merchant TE, Pappo A, Jenkins JJ, Shah AB, Kun LE: Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):433-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease.
  • PURPOSE: The occurrence of extraosseous Ewing's sarcoma (ES) in deep soft tissues has been well described, but cases in which this tumor occurs in a primary cutaneous or subcutaneous site have rarely been reported.
  • The superficial variant may be less aggressive than are the more common bony and deep soft tissue counterparts with an apparently favorable outcome.
  • A retrospective review of patients with cutaneous or subcutaneous ES was conducted to analyze outcome and patterns of failure.
  • METHODS AND MATERIALS: Between July 1985 and March 1997, 14 patients with cutaneous or subcutaneous ES were treated at St. Jude Children's Research Hospital.
  • Thirteen had definitive surgical resections, and one had biopsy of the mass at the time of referral.
  • All patients received chemotherapy, composed of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and dactinomycin.
  • Patients on institutional protocols received radiation (36 Gy) to the operative bed (150-180 cGy/fraction/day).
  • Thirteen patients had wide local excision of the primary tumors prior to enrollment on chemotherapy; surgical margins were negative (10), microscopically positive (2), and indeterminate (1).
  • The patient who had biopsy only received induction chemotherapy followed by definitive surgical resection and postoperative radiotherapy.
  • None of the patients has developed local recurrence or distant metastasis.
  • Several of the patients developed treatment-related sequelae, including veno-occlusive disease of the lung and hemorrhagic cystitis (1), myelodysplastic syndrome (1), chemotherapy-induced ovarian failure (1), moist desquamation (1), and dermatofibroma within the radiotherapy volumes (1).
  • CONCLUSIONS: Cutaneous and subcutaneous ES are associated with an indolent course and a favorable prognosis when treated with combined modality therapy.
  • Elimination of radiation therapy following complete resection has been tested in the POG 9354 trial.
  • The high rate of local control, low rate of metastatic disease, and excellent overall outcome may suggest a role for less intensive chemotherapy, as well as tailoring to diminish or avoid radiation therapy in completely resected cases, with a goal to minimize toxicity while maintaining a high cure rate.
  • [MeSH-major] Sarcoma, Ewing / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661351.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


83. Efe T, Heyse TJ, Schofer MD, Fuchs-Winkelmann S, Rexin P, Schmitt J: Malignant fibrous histiocytoma of the distal femur after an arthroscopic anterior cruciate ligament reconstruction: A case report and a review of the literature. BMC Cancer; 2010;10:264
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the distal femur after an arthroscopic anterior cruciate ligament reconstruction: A case report and a review of the literature.
  • To our knowledge, no case of osseous malignant fibrous histiocytoma after anterior cruciate ligament reconstruction is reported in the literature.
  • Biopsy determined a malignant fibrous histiocytoma.
  • After neoadjuvant chemotherapy, wide tumor resection and distal femur reconstruction with a silver-coated non-cemented tumor knee joint prosthesis was performed.
  • Adjuvant chemotherapy was continued according to the EURAMOS 1 protocol.
  • CONCLUSIONS: Though secondary malignant degeneration after orthopaedic implants or prostheses is not very likely, the attending physician should take this into consideration, especially if symptoms worsen severely over a short period of time.
  • [MeSH-major] Anterior Cruciate Ligament / surgery. Arthroscopy / adverse effects. Femoral Neoplasms / etiology. Histiocytoma, Malignant Fibrous / etiology. Tendon Transfer / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arthroplasty, Replacement, Knee. Biopsy. Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Pain / etiology. Reoperation. Rupture. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1979 Jan;10(1):57-70 [218883.001]
  • [Cites] Radiology. 1972 Sep;104(3):497-508 [4340636.001]
  • [Cites] Schweiz Med Wochenschr. 1980 Dec 27;110(52):2021-4 [6269177.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] Am J Surg Pathol. 1985 Dec;9(12):853-71 [3000204.001]
  • [Cites] Chemioterapia. 1988 Dec;7(6):406-13 [2851393.001]
  • [Cites] Orthop Rev. 1994 May;23(5):427-32 [8041576.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] J Bone Joint Surg Am. 2005 Feb;87(2):404-9 [15687167.001]
  • [Cites] Knee. 2006 Jun;13(3):184-8 [16603363.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:76-81 [16906097.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):504-7 [18038887.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jul;467(7):1820-5 [19229663.001]
  • [Cites] Burns. 1999 Dec;25(8):764-7 [10630863.001]
  • [Cites] Arthroscopy. 2001 May;17(5):461-76 [11337712.001]
  • [Cites] Orthopade. 2002 Aug;31(8):731-40 [12426751.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):214-7 [15021157.001]
  • [Cites] Dtsch Med Wochenschr. 1981 Mar 13;106(11):336-9 [6258891.001]
  • (PMID = 20529315.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2889898
  •  go-up   go-down


84. Schlott T, Taubert H, Fayyazi A, Schweyer S, Bartel F, Korabiowska M, Brinck U: Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide. Anticancer Res; 2004 Nov-Dec;24(6):3819-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
  • Soft tissue sarcomas frequently carry p53 mutations reducing chemotherapeutical response.
  • Especially malignant fibrous histiocytoma (MFH) reveals a reduced ifosfamide (IF) chemosensitivity when compared to other sarcoma entities.
  • The aim was to identify candidate genes possibly involved in the anti-apoptotic response of p53-deficient MFH cells during chemotherapy.
  • PCR, real-time RT-PCR and confocal laser scanning microscopy were applied on primary cultures of MFH cells containing defective p53 genes.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / genetics. Ifosfamide / pharmacology. Tumor Suppressor Protein p53 / deficiency
  • [MeSH-minor] Actins / biosynthesis. Actins / genetics. Alternative Splicing / drug effects. Caspase 3. Caspases / metabolism. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinases / biosynthesis. Cyclin-Dependent Kinases / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Humans. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retinoblastoma Protein / biosynthesis. Retinoblastoma Protein / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736417.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Antineoplastic Agents, Alkylating; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


85. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, Crownover R, Marks K, Muschler G, Joyce M, Zehr R, Bukowski R: Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs; 2000 Aug;18(3):253-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
  • PURPOSE: To assess the objective response rate, toxicity experienced, progression-free survival, and overall survival of patients with previously untreated advanced soft tissue sarcomas treated with a liposomal doxorubicin formulation (Doxil).
  • METHODS: Patients with metastatic or recurrent soft tissue sarcoma who had received no prior chemotherapy for advanced disease were treated with liposomal doxorubicin (Doxil) according to a two stage accrual design.
  • Leiomyosarcoma (7/15) and malignant fibrous histiocytoma (2/15) were the most common histologic diagnoses.
  • The median time to progression was 1.9 months (range 0.9-6.2).
  • CONCLUSION: Though well-tolerated, Doxil given according to this dose and schedule to patients with advanced soft tissue sarcoma had no significant therapeutic activity.
  • A correlation between older age and skin/mucosal toxicity of Doxil is suggested in this study but needs confirmation.
  • Future investigations of Doxil in soft tissue sarcomas should use a different schedule and dose.
  • [MeSH-major] Doxorubicin / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Carriers. Female. Follow-Up Studies. Humans. Liposomes. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1978 Mar;187(3):332-6 [637593.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Pharm Res. 1993 May;10(5):703-8 [8321835.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1655-9 [2681554.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):259-65 [1678995.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):32-5 [1736976.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):862-7 [2201431.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36 [2065067.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2111-7 [9164225.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):851-61 [3295129.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1131-3 [9834828.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 16;187(2):1098-105 [1356335.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Cancer. 1974 Jan;33(1):19-27 [4810094.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • (PMID = 10958594.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


86. Domson GF, Shahlaee A, Reith JD, Bush CH, Gibbs CP: Infarct-associated bone sarcomas. Clin Orthop Relat Res; 2009 Jul;467(7):1820-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty percent of cases arise about the knee and most are malignant fibrous histiocytomas.
  • We report 15 patients; 12 of 15 presented with a tumor around the knee.
  • Treatment was limb salvage in seven patients, amputation in six, and biopsy alone in two.
  • Two patients received chemotherapy and both were continuously disease-free at last followup.
  • Of 13 patients who received chemotherapy, eight (62%) were continuously disease-free at 24 months compared with 24% (13 of 54) of those who did not receive chemotherapy.
  • There is a trend suggesting adjuvant chemotherapy combined with appropriate surgery may improve patient outcomes.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Bone Neoplasms / complications. Histiocytoma, Malignant Fibrous / complications. Infarction / complications. Sarcoma / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 1999 Dec;3(6):370-3 [10594289.001]
  • [Cites] Clin Radiol. 1992 Jun;45(6):412-4 [1606803.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):67-73 [14765278.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jul-Aug;(118):180-3 [182426.001]
  • [Cites] Skeletal Radiol. 1991;20(2):137-40 [1850555.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):128-34 [1884531.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2418-30 [1423172.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Skeletal Radiol. 1993;22(1):58-61 [8430348.001]
  • [Cites] J Bone Joint Surg Am. 1995 May;77(5):777-81 [7744904.001]
  • [Cites] Arch Pathol Lab Med. 1996 May;120(5):482-9 [8639053.001]
  • [Cites] Clin Orthop Relat Res. 1996 Jun;(327):259-63 [8641072.001]
  • [Cites] Skeletal Radiol. 1998 Aug;27(8):463-7 [9765143.001]
  • [Cites] Skeletal Radiol. 1998 Oct;27(10):546-51 [9840390.001]
  • [Cites] J Bone Joint Surg Am. 1960 Jul;42-A:802-10 [13849880.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:76-81 [16906097.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • (PMID = 19229663.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2690751
  •  go-up   go-down


87. Patel SR: Radiation-induced sarcoma. Curr Treat Options Oncol; 2000 Aug;1(3):258-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced sarcomas can originate in either the irradiated bone or soft tissues.
  • The most common histologic subtypes are malignant fibrous histiocytoma (MFH) and osteosarcoma, although other histologies (eg, angiosarcoma, rhabdomyosarcoma) can occur.
  • Tumor size and grade are the two most important prognostic factors for soft tissue sarcomas, including those associated with radiation therapy.
  • The therapy is therefore dictated by the risk of distant metastases.
  • High-grade tumors that are larger than 5 cm should be treated with primary chemotherapy followed by a margin-negative surgical excision of the residual disease.
  • All low-grade tumors and high-grade tumors 5 cm or smaller should be treated with a margin-negative surgical excision, and systemic chemotherapy should be considered when a negative margin is difficult or impossible to accomplish.
  • Radiation-induced sarcomas (either MFH or osteosarcoma) originating in bone should be approached with primary chemotherapy followed by a margin-negative excision similar to de novo bone sarcomas.
  • The dose-intensity of the active agents should be adjusted appropriately for the age, performance status, and prior therapy in a given patient.
  • [MeSH-major] Bone Neoplasms / therapy. Neoplasms, Radiation-Induced / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1995 Aug;9(4):825-40 [7490244.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Lab Invest. 1998 Jun;78(6):727-33 [9645763.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2789-95 [10561354.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1379-85 [1365680.001]
  • [Cites] Cancer. 1971 Nov;28(5):1087-99 [5288429.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]
  • [Cites] Cancer. 1957 Jan-Feb;10(1):72-88 [13413802.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • (PMID = 12057168.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


88. Cağlar K, Güngör S, Akansoy S, Sakalli U, Orhan D, Cağlar M: Successful treatment of retroperitoneal giant cell-type malignant fibrous histiocytoma in a 5-year-old boy. Turk J Pediatr; 2007 Jul-Sep;49(3):307-11
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of retroperitoneal giant cell-type malignant fibrous histiocytoma in a 5-year-old boy.
  • Malignant fibrous histiocytoma, usually seen in patients older than 10 years, is an aggressive soft-tissue sarcoma occurring mostly in the extremities and the trunk, but it is extremely rare in children.
  • We report the clinical, radiological and pathologic features of a five-year-old boy who was diagnosed as a retroperitoneally originated malignant fibrous histiocytoma.
  • The patient with unresectable mass was successfully treated with multidisciplinary approach, with chemotherapy, surgery and radiotherapy, by using combined chemotherapy consisting of vincristine, cisplatinum, adriamycin, cyclophosphamide, actinomycin D and dacarbazine.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990587.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


89. Fritz MA, Sade B, Bauer TW, Wood BG, Lee JH: Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension. Acta Neurochir (Wien); 2006 Jan;148(1):73-6; discussion 76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension.
  • A very rare case of fibrous histiocytoma arising in the pterygopalatine fossa with intracranial extension is described.
  • The aggressive nature of our patient's tumor confirms previous observations that an aggressive radiographic appearance has prognostic value when dealing with skeletal and soft tissue tumors.
  • The benefit of multimodal therapy has not been established in these rare head and neck lesions.
  • In the subset of fibrous histiocytomas that invade bone, however adjunctive treatment with radiation and or chemotherapy may be appropriate.
  • [MeSH-major] Brain / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasm Recurrence, Local / pathology. Palate, Hard. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200478.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


90. Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG: Sarcomas with spindle cell morphology. Semin Oncol; 2009 Aug;36(4):324-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the days before the term "high-grade undifferentiated pleomorphic sarcoma" came into use, one of the most common sarcoma diagnoses was "malignant fibrous histiocytoma," and before that, in an era before immunohistochemistry, "fibrosarcoma" was used to describe most sarcomas.
  • As a very broad generalization, sarcomas with a spindle cell microscopic morphology occur in adults and are treated primarily with surgery and often adjuvant or neoadjuvant radiation as primary therapy.
  • In comparison to small round cell sarcomas such as Ewing sarcoma, the use of adjuvant chemotherapy remains controversial, and the sensitivity of these tumors to chemotherapy in the metastatic setting is highly variable.
  • [MeSH-minor] Chemotherapy, Adjuvant. Fibrosarcoma / genetics. Fibrosarcoma / pathology. Gene Fusion. Heat-Shock Response. Humans. Hyperthermia, Induced. Protein Kinase Inhibitors / therapeutic use. Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664493.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 62
  •  go-up   go-down


91. Pérez AF, Muñoz R, Morales J, Fereira E, Colina-Chourio J: [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review]. Invest Clin; 2008 Mar;49(1):103-10
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review].
  • [Transliterated title] Presentación de un caso de sarcoma maligno laríngeo, tratado mediante laringotomía transversa y revisión de la literatura.
  • Sarcomas of the larynx are rare neoplasmas that consitute less than 1% of laryngeal malignancies, and their usual treatment is surgery including partial and total laryngectomy and endoscopic laser cordotomy with reported 20% recurrence.
  • Due to previous positive experience from transversal laryngotomy in patients who underwent aritenoidectomy to treat bilateral cord paralysis after total thyroidectomy, the purpose of this work was to report on the surgical treatment of this rare case with such technique.
  • Thus, a 47 year-old physician who complained of hoarseness for four months without dyspnea, stridor, or dysphagia and with no history of irradiation or chemotherapy was operated after both endoscopic and tomographic studies showed a 3 to 4 cm glotic tumor in its right side, with no ulceration.
  • The pathology proved to be malignant fibrous histiocytoma.

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524336.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Venezuela
  • [Number-of-references] 24
  •  go-up   go-down


92. Atalar H, Başarir K, Yildiz Y, Sağlik Y: [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):271-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities].
  • OBJECTIVES: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity.
  • METHODS: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity.
  • Clinical and pathological data were analyzed including age, gender, affected extremity, presentation status (primary or recurrent), localization (proximal or distal), size, depth, and grade of the tumor, resection quality, adjuvant therapy, and the presence of distant metastasis at the time of diagnosis.
  • Adjuvant chemotherapy and radiotherapy were administered to 17 patients and 10 patients, respectively.
  • Two patients had distant metastasis at the time of diagnosis while eight patients developed distant metastasis within a mean of 13 months (range 7 to 20 months) postoperatively.
  • CONCLUSION: Patients with high-grade malignant fibrous histiocytoma have a poorer prognosis.
  • [MeSH-major] Extremities. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Recurrence, Local / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180555.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


93. Niamut SM, de Vries PA, van Putten JW, de Jong RS: [Eosinophilia caused by solid malignancy]. Ned Tijdschr Geneeskd; 2004 Sep 18;148(38):1883-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 48-year-old woman with exanthema, pruritus and eosinophilia was found upon further examination to have a small-cell bronchus carcinoma; after chemotherapy and radiotherapy there was an almost complete response and the skin symptoms disappeared.
  • A 70-year-old man who was recently treated due to primary malignant fibrous histiocytoma associated with eosinophilia became cachectic and anaemic.
  • It is important to recognise this phenomenon of paraneoplastic eosinophilia for the timely diagnosis and treatment of the underlying disease.

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15497785.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Kuhnen C, Müller KM, Steinau HU, Lehnhardt M: [Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings]. Pathologe; 2004 Nov;25(6):437-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings].
  • [Transliterated title] Therapieinduzierte Tumorregression in Weichgewebssarkomen des Erwachsenenalters. Morphologische Befunde.
  • Morphological findings of 21 soft tissue sarcomas of adulthood following preoperative chemo- and/or radiotherapy including perfusion therapy and resection are presented.
  • The therapy-induced changes included a spectrum ranging from total tumor regression up to still completely vital tumor (median of all cases: 30% vital tumor tissue).
  • So-called malignant fibrous histiocytoma (MFH) revealed a good tumor response to preoperatively administered therapy (regression grades I and II).
  • 30% up to 95% vital tumor tissue, non-responders).
  • Synovial sarcoma was characterized by regression grades III up to VI (i.e. up to 100% vital tumor tissue without any signs of regression, 83% non-responders).
  • Completely vital tumor was evident in 2 synovial sarcomas despite preoperative tumor therapy.
  • A grading of therapy-induced tumor regression in adult soft tissue sarcomas may best refer to already established grading schemes (e.g. according to the grading scheme for osteosarcomas following chemotherapy of Salzer-Kuntschik).
  • A report of sarcoma resection specimens should include the percentage of vital tumor tissue.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1982;3(6):531-42 [7155986.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Pathologe. 1985 Jan;6(1):16-23 [3983083.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1587-9 [11527682.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] Pathologe. 1985 Jan;6(1):3-7 [3983085.001]
  • [Cites] Pathologe. 1996 Jan;17(1):35-43 [8685094.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] Pathologe. 1997 Mar;18(2):131-40 [9244871.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):155-9 [10761796.001]
  • [Cites] Pathologe. 2004 May;25(3):193-201 [15138700.001]
  • (PMID = 15449026.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Follow-up information was available for 53 patients, with a mean follow-up of 81 months.
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Anglada Curado FJ, López Beltrán A, Prieto Castro R, Regueiro López JC, Leva Vallejo M, Alameda Aragoneses V, Blanco Espinosa A, Moreno Arcas P, Requena Tapia MJ: [Malignant fibrohistiocytoma of the bladder]. Actas Urol Esp; 2000 Jul-Aug;24(7):581-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Fibrohistiocitoma maligno de vejiga.
  • We report on new case of a rare vesical tumour.
  • We result the importance of immunohistochemistry and ultrastructural study to support the diagnosis of malignant fibrous histiocytoma of the urinary bladder.
  • After radical removal of tumour, adjuvant therapy is recommended both systemic chemotherapy and local radiotherapy, although survival rates are over 5.3 months after first therapeutical actuation.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11011450.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


97. Rapidis AD: Sarcomas of the head and neck in adult patients: current concepts and future perspectives. Expert Rev Anticancer Ther; 2008 Aug;8(8):1271-97
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck sarcomas account for 4 to less than 20% of total body sarcomas depending on the criteria, such as age of patients (pediatric vs adult population), type of sarcomas (soft-tissue vs bony sarcomas) and site of location.
  • Most head and neck sarcomas are of the soft-tissue type, with only 20% being of bony or cartilaginous origin.
  • Osteosarcomas, rhabdomyosarcomas, pleomorphic sarcomas (malignant fibrous histiocytomas), fibrosarcomas and angiosarcomas are among the most common histologic types of sarcoma found in the head and neck.
  • Surgery has been the primary therapeutic approach for the management of head and neck sarcomas.
  • Conflicting results have been reported on the benefit from the use of chemotherapy as an adjuvant or neoadjuvant regimen, especially for high-grade sarcomas in long-term survival or local disease control.
  • Encouraging results have recently been reported with the use of molecular targeted therapies with tyrosine kinase inhibitors and antiangiogenetic agents.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699765.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Su HW, Hsu CS, Lin YH, Hsu MI, Chiang HK, Chou SY: Malignant fibrous histiocytoma during pregnancy: a case report. Taiwan J Obstet Gynecol; 2006 Mar;45(1):86-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma during pregnancy: a case report.
  • OBJECTIVE: We present a case of a 38-year-old postpartum woman who had antepartal undiagnosed sarcoma with multiple metastasis.
  • Although the patient underwent aggressive treatment with surgery and chemotherapy, she died 3 months after the vaginal delivery of a healthy female infant weighing 2,090 g at 35 weeks of gestation.
  • All the removed specimens were sent for pathologic examination, and the results showed a sarcoma favoring malignant fibrous histiocytoma with its primary origin in the left atrium.
  • [MeSH-major] Bone Neoplasms / secondary. Heart Neoplasms / pathology. Histiocytoma, Malignant Fibrous / secondary. Humerus. Pregnancy Complications, Neoplastic. Shoulder Joint
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Heart Atria. Humans. Infant, Newborn. Postpartum Period. Pregnancy. Pregnancy Trimester, Third. Tomography, X-Ray Computed


99. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the abdominal cavity: report of a case.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Kariya S, Aoji K, Kuyama K, Akagi H, Fukazawa M, Nishizaki K: Malignant fibrous histiocytoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):315-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • Primary malignant fibrous histiocytoma (MFH) arising in a major salivary gland is rare.
  • The patient was a 54-year-old man diagnosed as having pleomorphic type of MFH after extended total parotidectomy.
  • Accordingly treatment consisted in the resection of MFH and radiotherapy in combination with chemotherapy using carboplatin (CBDCA).
  • This postoperative therapy was effective in controlling the growth of the remaining tumor tissue.
  • As the patient showed no signs of local recurrence and distant metastasis for 5 years, plastic surgery was performed to improve the serious deformation of the face with a free anterolateral thigh flap.
  • [MeSH-major] Histiocytoma, Benign Fibrous. Parotid Gland. Salivary Gland Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927301.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down






Advertisement